1
YNHCH Pediatric Specialty Center at Trumbull
Trumbull Pediatric Specialty Center
5520 Park Avenue, Ste 600
Trumbull, CT 06611
1 of 3
- YNHCH Pediatric Specialty Center at TrumbullTrumbull Pediatric Specialty Center5520 Park Avenue, Ste 600Trumbull, CT 06611
- Smilow Cancer HospitalSmilow Cancer Hospital at Yale New Haven35 Park Street, Wing North Pavilion Fl 7New Haven, CT 06511
- YNHCH Pediatric Specialty Center at Old SaybrookOld Saybrook Medical Center633 Middlesex Turnpike, Ste 110Old Saybrook, CT 06475
Michael Recht, MD, PhD, MBA
he/him/his
Pediatric Hematology & Oncology
Telehealth is available
Patient type treated
Child
Accepting new patients
Yes
Referral required
From patients or physicians
Biography
Michael Recht, MD, PhD, is a pediatric hematologist who focuses on treating children, adolescents, and young adults with bleeding and clotting disorders.
Dr. Recht is a professor of clinical pediatrics at Yale School of Medicine. He has been actively involved in more than 110 clinical trials, including research on gene therapy for hemophilia. Dr. Recht also serves as the chief medical and scientific officer for the National Bleeding Disorders Foundation. In this role, he helps shape the scientific direction and research strategy of the organization, working to advance the understanding and treatment of bleeding disorders. Dr. Recht received his medical and doctoral degrees from the University of Wisconsin-Madison. He completed his residency in pediatrics and fellowship in pediatric hematology-oncology at Yale New Haven Hospital.
Titles
- Professor of Clinical Pediatrics (Hematology/Oncology)
- Chief Medical and Scientific Officer, National Hemophilia Foundation, National Hemophilia Foundation
Education & Training
- MBAOregon Health & Science University/Portland State University (2016)
- FellowYale University School of Medicine (1998)
- ResidentYale New Haven Hospital (1995)
- MDUniversity of Wisconsin-Madison (1992)
- PhDUniversity of Wisconsin-Madison (1990)
Additional Information
Publications
- von Drygalski A, Gomez E, Giermasz A, Castaman G, Key N, Lattimore S, Leebeek F, Miesbach W, Recht M, Monahan P, Le Quellec S, Pipe S. Completion of Phase 2b trial of etranacogene dezaparvovec gene therapy in patients with hemophilia B over 5 years. Blood Advances 2025 PMID: 40188458, DOI: 10.1182/bloodadvances.2024015291.
- Konkle B, Peyvandi F, Foster G, Hermans C, La Mura V, Leavitt A, Lillicrap D, Mahlangu J, Ozelo M, Pipe S, Recht M, Srivastava A, Young G, Miesbach W. Corticosteroid use to mitigate transaminitis-associated decline in FVIII levels following valoctocogene roxaparvovec gene therapy: clinical practice guidance. Journal Of Thrombosis And Haemostasis 2025 PMID: 40090623, DOI: 10.1016/j.jtha.2025.02.042.
- Chrisentery‐Singleton T, Gattone P, Gerber C, Mills K, Miles M, Rotellini D, Santaella M, Valentino L, Watson C, Recht M. American Thrombosis and Hemostasis Network: National Bleeding Disorders Foundation Data Commons: Better Together. Haemophilia 2025 PMID: 39982786, DOI: 10.1111/hae.70011.
- Valentino L, Santaella M, Carlson S, Recht M. Contemporary approaches to treat people with hemophilia: what’s new and what’s not? Research And Practice In Thrombosis And Haemostasis 2025, 9: 102696. PMID: 40084158, PMCID: PMC11905833, DOI: 10.1016/j.rpth.2025.102696.
- Dunn A, Dargaud Y, Abajas Y, Carcao M, Castaman G, Giermasz A, Hermans C, Jiménez‐Yuste V, Lewandowska M, Mahlangu J, Meeks S, Miesbach W, Recht M, Salinas V, Chrisentery‐Singleton T, Bonzo D, Mitchell I, Wilkinson T, Young G. Bleed treatment with eptacog beta (rFVIIa) results in a low incidence of rebleeding in adult and adolescent patients with haemophilia A or B with inhibitors. Haemophilia 2024, 31: 78-86. PMID: 39676340, PMCID: PMC11780187, DOI: 10.1111/hae.15109.
- Skinner M, Albisetti M, Ardila J, Astermark J, Blatny J, Carcao M, Chowdary P, Connell N, Crato M, Dargaud Y, d'Oiron R, Dunn A, Escobar M, Escuriola‐Ettingshausen C, Gouider E, Harroche A, Hermans C, Jimenez‐Yuste V, Kaczmarek R, Kenet G, Khoo L, Klamroth R, Langer F, Lillicrap D, Mahlangu J, Male C, Matsushita T, Meunier S, Miesbach W, Nolan B, Oldenburg J, O'Mahony B, Ozelo M, Pierce G, Ramos G, Recht M, Romero‐Lux O, Rotellini D, Santoro R, Singleton T, Srivastava A, Susen S, Talks K, Tran H, Valentino L, Windyga J, Yang R, Mancuso M, also on behalf of AICE A. Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and Von Willebrand Disease. Haemophilia 2024 PMID: 39648854, DOI: 10.1111/hae.15136.
- Albisetti M, Ardila J, Astermark J, Blatny J, Carcao M, Chowdary P, Connell N, Crato M, Dargaud Y, d'Oiron R, Dunn A, Escobar M, Ettingshausen C, Fischer K, Gouider E, Harroche A, Hermans C, Jimenez‐Yuste V, Kaczmarek R, Kenet G, Khoo L, Klamroth R, Langer F, Lillicrap D, Mahlangu J, Male C, Mancuso M, Matsushita T, Meunier S, Miesbach W, Nolan B, Oldenburg J, O'Mahony B, Ozelo M, Pierce G, Ramos G, Recht M, Romero‐Lux O, Rotellini D, Santoro R, Singleton T, Skinner M, Srivastava A, Susen S, Talks K, Tran H, Valentino L, Windyga J, Yang R, also on behalf of AICE A. International Society on Thrombosis and Haemostasis Clinical Practice Guideline for Treatment of Congenital Haemophilia—A Critical Appraisal. Haemophilia 2024 PMID: 39642092, DOI: 10.1111/hae.15135.
- Chandler M, Moulton T, Charafi L, Charlet J, Recht M. Effectiveness of Damoctocog Alfa Pegol to Treat Patients With Hemophilia A Enrolled in the ATHNdataset. European Journal Of Haematology 2024, 114: 448-457. PMID: 39558414, PMCID: PMC11798759, DOI: 10.1111/ejh.14337.
- Corrales-Medina F, Afari-Dwamena N, Blair A, Carpenter S, Chrisentery-Singleton T, Daoud N, Janbain M, Raffini L, Schwartz J, Zia A, Recht M. ATHN Transcends Hemophilia Natural History Arm: Baseline Characteristics, Adverse Events, and Self-Reported Health Status of Individuals with Hemophilia A and B. Blood 2024, 144: 1204. DOI: 10.1182/blood-2024-198548.
- Buckner T, Kessler C, Castaman G, Hermans C, Jimenez-Yuste V, Mahlangu J, Miesbach W, Oldenburg J, Recht M, Valentino L, Wheeler A, Pipe S. Pain Reduction Following Treatment of Bleeding Episodes with Eptacog Beta in Adults and Adolescents with Hemophilia A or B Complicated By Inhibitors. Blood 2024, 144: 3972-3972. DOI: 10.1182/blood-2024-194935.
- Youkhana K, Batsuli G, Acharya S, Khan O, Tran D, Dvorak A, Recht M, Young G, Sidonio R, Abajas Y. Real‐world effectiveness of eptacog beta in patients with haemophilia and inhibitors: A multi‐institutional case series. Haemophilia 2024, 30: 1321-1331. PMID: 39297369, PMCID: PMC11659498, DOI: 10.1111/hae.15094.
- DeSancho M, Suvar E, Roberts J, Tarantino M, Schwartz J, Callis J, Recht M. Hereditary antithrombin deficiency pilot project registry from the American Thrombosis and Hemostasis Network. Journal Of Thrombosis And Haemostasis 2024, 22: 3183-3190. PMID: 39151704, DOI: 10.1016/j.jtha.2024.07.026.
- Pierce G, O'Mahony B, Kaczmarek R, Skinner M, Makris M, Peyvandi F, Srivastava A, Hermans C, World Federation of Hemophilia Coagulation Products Supply S, Crato M, Dunn A, Gouider E, Mahlangu J, Page D, Pipe S, Recht M, Sannie T, Schaefer N, Schlenkrich U, Garrido C. Risk of harm to people with haemophilia from the 2023 WHO Essential Medicines List. The Lancet Haematology 2024, 11: e638-e640. PMID: 39116903, DOI: 10.1016/s2352-3026(24)00223-0.
- Nolan B, Recht M, Rendo P, Falk A, Foster M, Casiano S, Rauch A, Shapiro A. Prophylaxis with recombinant factor IX Fc fusion protein reduces the risk of bleeding and delays time to first spontaneous bleed event in previously untreated patients with haemophilia B: A post hoc analysis of the PUPs B‐LONG study. European Journal Of Haematology 2024, 113: 485-492. PMID: 38922990, DOI: 10.1111/ejh.14252.
- Hu J, Chandler M, Manuel C, Caicedo J, Denne M, Ewenstein B, Mokdad A, Xing S, Recht M. Risk of Intracranial Hemorrhage in Persons with Hemophilia A in the United States: Real-World Retrospective Cohort Study Using the ATHNdataset. Journal Of Blood Medicine 2024, 15: 191-205. PMID: 38699197, PMCID: PMC11063465, DOI: 10.2147/jbm.s443380.
- Itzler R, Buckner T, Leebeek F, Miller J, Recht M, Drelich D, Monahan P, Pipe S. Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE‐B trial 2 years after gene therapy. Haemophilia 2024, 30: 709-719. PMID: 38462823, DOI: 10.1111/hae.14977.
- Ragni M, Callis J, Daoud N, Hu B, Manuel M, Santos J, Schwartz J, Friedman K, Kouides P, Kuriakose P, Leavitt A, Lim M, Machin N, Recht M, Chrisentery‐Singleton T. Observational cohort study of long‐term outcomes of liver transplantation in haemophilia. Haemophilia 2023, 30: 87-97. PMID: 38111071, DOI: 10.1111/hae.14910.
- Chandler M, Charlet J, Moulton T, Recht M. Real-World Data on Hemophilia a Patients Transitioning from Bay 81-8973 to Bay 94-9027 and from Bay 14-2222 to Bay 81-8973 and then to Bay 94-9027 in the Athndataset. Blood 2023, 142: 5479. DOI: 10.1182/blood-2023-188995.
- Reiss U, Davidoff A, Tuddenham E, Chowdary P, McIntosh J, Riddell A, Pie A, Batty P, Calvert J, Mangles S, Mahlangu J, Haley K, Recht M, Shen Y, Halka K, Zhou J, Kang G, Okhomina V, Morton C, Nathwani A. Stable Therapeutic Transgenic FIX Levels for More Than 10 Years in Subjects with Severe Hemophilia B Who Received scAAV2/8-LP1-Hfixco Adeno-Associated Virus Gene Therapy. Blood 2023, 142: 1056. DOI: 10.1182/blood-2023-186891.
- Santaella M, Raimundo K, Schuldt R, Recht M. Comparison of Projected Hemophilia a Populations Residing in Hospital Referral Regions with and without Hemophilia Treatment Centers in the US. Blood 2023, 142: 3696. DOI: 10.1182/blood-2023-181009.
- Buckner T, Daoud N, Lee L, Lim E, Schwartz J, Raimundo K, Recht M. Quality of Life in Emicizumab-Treated People with Hemophilia A in the ATHN 7 Hemophilia Natural History Study - an Assessment of Baseline PROMIS®-29 Scores. Blood 2023, 142: 3998. DOI: 10.1182/blood-2023-174092.
- Santaella M, Carlson L, DiMichele D, Norris K, Valadez S, Valentino L, Vazquez E, Witkop M, Recht M. Walking the Walk: Inclusion of Lived Experience Experts in the Design of the National Hemophilia Foundation's National Research Blueprint for Those Living with Inherited Bleeding Disorders. Blood 2023, 142: 7216. DOI: 10.1182/blood-2023-186109.
- Chrisentery-Singleton T, O'Neill C, Rea C, Amin J, Recht M. Athn Transcends Natural History Cohort Study of Bleeding Symptoms and Treatment Outcomes in Patients with Glanzmann Thrombasthenia. Blood 2023, 142: 5457. DOI: 10.1182/blood-2023-190090.
- DeSancho M, Suvar E, Roberts J, Tarantino M, Santos J, Manuel M, Recht M. PB0987 Hereditary Antithrombin Deficiency Pilot Project Registry from the American Thrombosis and Hemostasis Network (ATHN). Research And Practice In Thrombosis And Haemostasis 2023, 7: 101802. DOI: 10.1016/j.rpth.2023.101802.
- Tootoonchian E, Stonebraker J, Iorio A, El-Ekiaby M, Gouider E, Makris M, O'Hara J, Recht M, Pierce G, Coffin D. PB0837 Analysis of the Change in Diagnosis of von Willebrand Disease by Region and Economic Status. Research And Practice In Thrombosis And Haemostasis 2023, 7: 101562. DOI: 10.1016/j.rpth.2023.101562.
- Singleton T, Acharya S, Ahuja S, Amos L, Bonzo D, Eason A, Escobar M, Knoll C, Kuriakose P, Lagrue E, Recht M, Sullivan S, Quon D, Reding M. PB0323 Preliminary Analysis of ATHN 16: Real-World Safety of Eptacog Beta. Research And Practice In Thrombosis And Haemostasis 2023, 7: 101463. DOI: 10.1016/j.rpth.2023.101463.
- Malec L, Bialas R, O'Neill C, Thibaudeau K, Warner E, Weigel E, Recht M. PB0229 Designing the Ryplazim® (Plasminogen, Human-tvmh) Arm of Athn Transends: Safety and Effectiveness in People with Plasminogen Deficiency. Research And Practice In Thrombosis And Haemostasis 2023, 7: 101264. DOI: 10.1016/j.rpth.2023.101264.
- Youttananukorn T, Konkle B, Coffin D, Naccache M, Clark C, George L, Iorio A, Miesbach W, Noone D, Peyvandi F, Pipe S, Recht M, Skinner M, Valentino L, Mahlangu J, Pierce G. PB0191 myGTR: A Patient Engagement Tool from the World Federation of Hemophilia Gene Therapy Registry. Research And Practice In Thrombosis And Haemostasis 2023, 7: 101212. DOI: 10.1016/j.rpth.2023.101212.
- Buckner T, Daoud N, Lee L, Morton P, O'Neill C, Wang M, Recht M. PB0625 Emicizumab Prophylaxis in People with Hemophilia A Aged >50 Years withComorbidities:ExperienceFromtheATHN7Hemophilia Natural History Study. Research And Practice In Thrombosis And Haemostasis 2023, 7: 101210. DOI: 10.1016/j.rpth.2023.101210.
- Malec L, Carpenter S, O'Neill C, Thornburg C, Recht M. PB0629 Designing the Efanesoctocog Alfa Module of ATHN Transcends: Safety, Tolerability, and Effectiveness in Previously Untreated Patients with Hemophilia A. Research And Practice In Thrombosis And Haemostasis 2023, 7: 101199. DOI: 10.1016/j.rpth.2023.101199.
- Recht M, Charlet J, Moulton T, Chandler M. PB0672 Real-World Data on Hemophilia A Patients Switching to Either BAY 94-9027 or BAY 81-8973 from Emicizumab Using the ATHNdataset. Research And Practice In Thrombosis And Haemostasis 2023, 7: 101169. DOI: 10.1016/j.rpth.2023.101169.
- Ragni M, Hu B, Callis J, Manuel M, Santos J, Friedman K, Kouides P, Kuriakose P, Leavitt A, Lim M, Machin N, Recht M. PB1241 ATHN 11: Observational Study of Long-Term Outcomes of Liver Transplantation. Research And Practice In Thrombosis And Haemostasis 2023, 7: 101135. DOI: 10.1016/j.rpth.2023.101135.
- Recht M, Charlet J, Moulton T, Chandler M. PB1278 Real-World Data on Hemophilia A Patients with Inhibitors Switching to Either BAY 94-9027 or BAY 81-8973 in the ATHNdataset. Research And Practice In Thrombosis And Haemostasis 2023, 7: 101124. DOI: 10.1016/j.rpth.2023.101124.
- Recht M, Charafi L, Moulton T, Chandler M. PB1291 Joint Range of Motion Findings Among Female Patients with Hemophilia A from the ATHNdataset. Research And Practice In Thrombosis And Haemostasis 2023, 7: 101103. DOI: 10.1016/j.rpth.2023.101103.
- Nugent D, Williams S, Ashburner C, Crook N, Momoh H, Recht M, Chandler M, Shapiro A. OC 75.1 First US Rare Bleeding Disorder Genotype-Phenotype Registry (ATHN 10) Discovers Many Individuals with Both Novel and Multiple Variants using a Customized 30-Gene Next-Generation Sequencing Panel. Research And Practice In Thrombosis And Haemostasis 2023, 7: 100478. DOI: 10.1016/j.rpth.2023.100478.
- Miesbach W, Recht M, Key N, Guillen-Gonzalez R, Sivamurthy K, Monahan P, Pipe S. OC 52.1 Assessing the Safety Profile of AMT-060 and Etranacogene Dezaparvovec Gene Therapies Across Clinical Trials in People with Severe/Moderately Severe Hemophilia B. Research And Practice In Thrombosis And Haemostasis 2023, 7: 100456. DOI: 10.1016/j.rpth.2023.100456.
- Pipe S, Leebeek F, Recht M, Key N, Lattimore S, Castaman G, Coppens M, Li Y, Monahan P, Miesbach W. OC 52.5 Phase 3 HOPE-B Trial of Etranacogene Dezaparvovec in Severe/Moderately Severe Hemophilia B: A Post Hoc Responder Analysis of Participants Who Received Full Dose and Responded to Treatment. Research And Practice In Thrombosis And Haemostasis 2023, 7: 100448. DOI: 10.1016/j.rpth.2023.100448.
- Konkle B, Coffin D, Naccache M, Youttananukorn T, Clark C, George L, Iorio A, Miesbach W, Noone D, Peyvandi F, Pipe S, Recht M, Skinner M, Valentino L, Mahlangu J, Pierce G. OC 20.5 The WFH Gene Therapy Registry: A Collaborative Approach Towards a Global Resource for the Long-Term Follow-up of People with Hemophilia Treated with Gene Therapy. Research And Practice In Thrombosis And Haemostasis 2023, 7: 100445. DOI: 10.1016/j.rpth.2023.100445.
- Chelle P, Hajducek D, Daoud N, Iserman E, Gerber C, Germini F, Iorio A, Edginton A, Recht M. OC 24.2 Estimated Factor VIII Activity Levels at the Time of Bleeding Events in Individuals with Hemophilia a Without Inhibitors. Research And Practice In Thrombosis And Haemostasis 2023, 7: 100436. DOI: 10.1016/j.rpth.2023.100436.
- von Drygalski A, Gomez E, Giermasz A, Castaman G, Key N, Lattimore S, Leebeek F, Miesbach W, Recht M, Gut R, Dolmetsch R, Monahan P, Le Quellec S, Pipe S. Stable and durable factor IX levels in hemophilia B patients over 3 years post etranacogene dezaparvovec gene therapy. Blood Advances 2023, 7: 5671-5679. PMID: 36490302, PMCID: PMC10539871, DOI: 10.1182/bloodadvances.2022008886.
- Nugent D, Acharya S, Baumann K, Bedrosian C, Bialas R, Brown K, Corzo D, Haidar A, Hayward C, Marks P, Menegatti M, Miller M, Nammacher K, Palla R, Peltier S, Pruthi R, Recht M, Sørensen B, Tarantino M, Wolberg A, Shapiro A. Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for ultra-rare inherited bleeding disorders. Expert Review Of Hematology 2023, 16: 55-70. PMID: 36920862, PMCID: PMC10020868, DOI: 10.1080/17474086.2023.2175661.
- Valentino L, Witkop M, Santaella M, DiMichele D, Recht M. The National Hemophilia Foundation’s State of the Science Research Summit: the foundation of a national research blueprint for inherited bleeding disorders. Expert Review Of Hematology 2023, 16: 1-5. PMID: 36920858, DOI: 10.1080/17474086.2023.2178412.
- Valentino L, Witkop M, Santaella M, DiMichele D, Recht M. The National Hemophilia Foundation State of the Science Research Summit initiative: executive summary. Expert Review Of Hematology 2023, 16: 129-134. PMID: 36920857, DOI: 10.1080/17474086.2023.2181782.
- Messenger H, Kulkarni R, Recht M, He C. A Retrospective Analysis of the American Thrombosis and Hemostasis Network Dataset Describing Outcomes of Dental Extractions in Persons with Hemophilia. Journal Of Clinical Medicine 2023, 12: 1839. PMID: 36902626, PMCID: PMC10002874, DOI: 10.3390/jcm12051839.
- Parker K, Durben N, Oleson D, Yu Y, Lim J, Recht M, Lindemulder S. Hopping as an Indicator of Chemotoxicity: Gait Analysis in Patients With Leukemia and Lymphoma. Journal Of Pediatric Hematology/Oncology 2023, 45: e582-e589. PMID: 36898017, DOI: 10.1097/mph.0000000000002645.
- Pipe S, Leebeek F, Recht M, Key N, Castaman G, Miesbach W, Lattimore S, Peerlinck K, Van der Valk P, Coppens M, Kampmann P, Meijer K, O’Connell N, Pasi K, Hart D, Kazmi R, Astermark J, Hermans C, Klamroth R, Lemons R, Visweshwar N, von Drygalski A, Young G, Crary S, Escobar M, Gomez E, Kruse-Jarres R, Quon D, Symington E, Wang M, Wheeler A, Gut R, Liu Y, Dolmetsch R, Cooper D, Li Y, Goldstein B, Monahan P. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B. New England Journal Of Medicine 2023, 388: 706-718. PMID: 36812434, DOI: 10.1056/nejmoa2211644.
- Pipe W, Leebeek W, Recht M, Key S, Lattimore S, Castaman G, Coppens M, Cooper D, Gut R, Slawka S, Verweij S, Dolmetsch R, Li Y, Monahan P, Miesbach W. Adults with severe or moderately severe haemophilia B receiving etranacogene dezaparvovec in the HOPE-B phase 3 trial experience a stable increase in mean Factor IX activity levels and durable haemostatic protection after 24 months’ follow-up. Hämostaseologie 2023, 43: s44-s45. DOI: 10.1055/s-0042-1760523.
- Miesbach W, Recht M, Key N, Sivamurthy K, Monahan E, Pipe W. Durability of Factor IX activity and bleeding rate in people with severe or moderately severe haemophilia B after long-term follow-up in the phase 1/2 Study of AMT-060, and phase 2b and phase 3 studies of etranacogene dezaparvovec (AMT-061). Hämostaseologie 2023, 43: s46-s47. DOI: 10.1055/s-0042-1760526.
- Pipe W, Leebeek W, Recht M, Key S, Lattimore S, Castaman G, Cooper D, Verweij S, Dolmetsch R, Tarrant J, Li Y, Monahan E, Miesbach W. Durability of bleeding protection and Factor IX activity in individuals with and without adeno-associated virus serotype 5 neutralising antibodies (Titres <1:700) in the phase 3 HOPE-B trial of etranacogene dezaparvovec gene therapy for haemophilia B. Hämostaseologie 2023, 43: s45-s45. DOI: 10.1055/s-0042-1760524.
- Corrales-Medina F, Raffini L, Recht M, Santos J, Thornburg C, Davila J, Investigators A. Direct oral anticoagulants in pediatric venous thromboembolism: Experience in specialized pediatric hemostasis centers in the United States. Research And Practice In Thrombosis And Haemostasis 2022, 7: 100001. PMID: 36970740, PMCID: PMC10031368, DOI: 10.1016/j.rpth.2022.100001.
- Pipe S, Leebeek F, Recht M, Key N, Lattimore S, Castaman G, Coppens M, Cooper D, Gut R, Slawka S, Verweij S, Dolmetsch R, Li Y, Monahan P, Miesbach W. Adults with Severe or Moderately Severe Hemophilia B Receiving Etranacogene Dezaparvovec in the HOPE-B Phase 3 Clinical Trial Continue to Experience a Stable Increase in Mean Factor IX Activity Levels and Durable Hemostatic Protection after 24 Months’ Follow-up. Blood 2022, 140: 4910-4912. DOI: 10.1182/blood-2022-166135.
- Hu B, Chandler M, Manuel M, Caicedo J, Denne M, Ewenstein B, Mokdad A, Xing S, Recht M. Risk of Intracranial Hemorrhage in US Patients with Hemophilia a: Real-World Retrospective Cohort Study Using the Athndataset. Blood 2022, 140: 2722-2723. DOI: 10.1182/blood-2022-163861.
- Chrisentery-Singleton T, Amos L, Bonzo D, Escobar M, Giermasz A, Lagrue E, Knoll C, Nasr S, Recht M, Sullivan S, Quon D, Reding M. A Preliminary Analysis of Athn 16: Safety of Coagulation Factor VIIa (recombinant)-Jncw for the Treatment of Bleeding Events in Patients with Congenital Hemophilia a or B with Inhibitors. Blood 2022, 140: 11360-11361. DOI: 10.1182/blood-2022-163372.
- Weyand A, Chandler M, Fedor C, Recht M, Sidonio R. Quality of Life in Patients with Clinically Severe Von Willebrand Disease: Interim Analysis of Athn 9: A Natural History Study for People with Severe Von Willebrand Disease (VWD). Blood 2022, 140: 5600-5602. DOI: 10.1182/blood-2022-163302.
- Carpenter S, Chandler M, Guerrera M, Malec L, Manuel M, Recht M, Reiss U, Sidonio R, Tarango C, Van den Berg M, Wang M, Thornburg C. U.S. Cohort Study of Previously Untreated Patients with Congenital Hemophilia (ATHN 8: PUPs Study): Inhibitor Development and Treatment Characteristics. Blood 2022, 140: 63-64. DOI: 10.1182/blood-2022-162660.
- Swaminathan N, Hu B, Currie A, Kulkarni R, Pipe S, Recht M, Kouides P, Sharathkumar A. Characterization of Bleeding and Laboratory Phenotype of Carriers of Hemophilia and Trends of Utilization of Factor Concentrates and Hemostatic Therapies: Analysis of the National Athndataset. Blood 2022, 140: 59-60. DOI: 10.1182/blood-2022-158861.
- Decker-Palmer M, Mathias S, Colwell H, Crosby R, Gentile B, Chupka J, Sidonio R, Recht M, Shapiro A, Zazzali J. Performance of the Comprehensive Assessment Tool for Challenges in Hemophilia (CATCH) 2.0. Blood 2022, 140: 11328-11329. DOI: 10.1182/blood-2022-157932.
- Recht M, Daoud N, Lee L, Morton P, Raffini L. Emicizumab and Females with Hemophilia A: Case Series from ATHN 7. Blood 2022, 140: 2745-2746. DOI: 10.1182/blood-2022-157754.
- Dunn A, Dargaud Y, Abajas Y, Carcao M, Castaman G, Giermasz A, Hermans C, Lewandowska M, Mahlangu J, Meeks S, Miesbach W, Recht M, Salinas V, Chrisentery-Singleton T, Wang H, Mitchell I, Young G. Eptacog Beta (rFVIIa) Has a Low Incidence of Spontaneous Rebleeding through 24 and 48 Hours in Adult and Adolescent Patients with Hemophilia A or B with Inhibitors. Blood 2022, 140: 8485-8488. DOI: 10.1182/blood-2022-157343.
- Witkop M, Santaella M, Recht M, Norris K, Spitale B, Vasquez E, DiMichele D, Mills K. National Hemophilia Foundation Champions a National Research Blueprint Defining a Community-Coordinated Research Ecosystem to Accelerate Progress in Inherited Bleeding Disorders. Blood 2022, 140: 5021-5022. DOI: 10.1182/blood-2022-170842.
- DeSancho M, Suvar E, Roberts J, Tarantino M, Santos J, Recht M. Hereditary Antithrombin Deficiency Pilot Project Registry from the American Thrombosis and Hemostasis Network (ATHN). Blood 2022, 140: 5670-5672. DOI: 10.1182/blood-2022-168179.
- Miesbach W, Recht M, Key N, Sivamurthy K, Monahan P, Pipe S. Durability of Factor IX Activity and Bleeding Rate in People with Severe or Moderately Severe Hemophilia B after 5 Years of Follow-up in the Phase 1/2 Study of AMT-060, and after 3 Years of Follow-up in the Phase 2b and 2 Years of Follow-up in the Phase 3 Studies of Etranacogene Dezaparvovec (AMT-061). Blood 2022, 140: 4913-4914. DOI: 10.1182/blood-2022-166810.
- Pipe S, Leebeek F, Recht M, Key N, Lattimore S, Castaman G, Cooper D, Verweij S, Dolmetsch R, Tarrant J, Li Y, Monahan P, Miesbach W. Durability of Bleeding Protection and Factor IX Activity Levels Are Demonstrated in Individuals with and without Adeno-Associated Virus Serotype 5 Neutralizing Antibodies (Titers <1:700) with Comparable Safety in the Phase 3 HOPE-B Clinical Trial of Etranacogene Dezaparvovec Gene Therapy for Hemophilia B. Blood 2022, 140: 4904-4906. DOI: 10.1182/blood-2022-166745.
- Chandler M, Charlet J, Moulton T, Recht M. Real-World Use of Octocog Alfa and Damoctocog Alfa Pegol in Women with Hemophilia a from the ATHNdataset. Blood 2022, 140: 2751-2752. DOI: 10.1182/blood-2022-166669.
- Johnsen J, Fletcher S, Dove A, McCracken H, Martin B, Kircher M, Josephson N, Shendure J, Ruuska S, Valentino L, Pierce G, Watson C, Cheng D, Recht M, Konkle B. Results of genetic analysis of 11 341 participants enrolled in the My Life, Our Future hemophilia genotyping initiative in the United States. Journal Of Thrombosis And Haemostasis 2022, 20: 2022-2034. PMID: 35770352, DOI: 10.1111/jth.15805.
- Roberts J, Richardson S, Miles M, Stanley J, Chapman C, Denne M, Caicedo J, Rockwood K, Recht M. The GOAL‐Hēm journey: Shared decision making and patient‐centred outcomes. Haemophilia 2022, 28: 784-795. PMID: 35728103, PMCID: PMC9546188, DOI: 10.1111/hae.14608.
- Valentino L, Witkop M, Santaella M, DiMichele D, Recht M. Building the blueprint: Formulating a community‐generated national plan for future research in inherited bleeding disorders. Haemophilia 2022, 28: 760-768. PMID: 35700441, PMCID: PMC9546016, DOI: 10.1111/hae.14588.
- Rauch A, Valentino L, Mills K, Witkop M, Santaella M, DiMichele D, Recht M, Susen S. Big picture initiatives in bleeding disorders. Haemophilia 2022, 28: 53-60. PMID: 35521733, DOI: 10.1111/hae.14532.
- Pipe S, Hermans C, Chitlur M, Carcao M, Castaman G, Davis J, Ducore J, Dunn A, Escobar M, Journeycake J, Khan O, Mahlangu J, Meeks S, Mitha I, Négrier C, Nowak‐Göttl U, Recht M, Chrisentery‐Singleton T, Stasyshyn O, Vilchevska K, Martinez L, Wang M, Windyga J, Young G, Alexander W, Bonzo D, Macie C, Mitchell I, Sauty E, Wilkinson T, Shapiro A. Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors. Haemophilia 2022, 28: 548-556. PMID: 35475308, PMCID: PMC9542908, DOI: 10.1111/hae.14563.
- Recht M, He C, Chen E, Cheng D, Solari P, Hinds D. Resource utilization and treatment costs of patients with severe hemophilia A: Real‐world data from the ATHNdataset. EJHaem 2022, 3: 341-352. PMID: 35846041, PMCID: PMC9176109, DOI: 10.1002/jha2.412.
- Burke T, Shaikh A, Ali T, Li N, Curtis R, Diego D, Recht M, Sannie T, Skinner M, O’Hara J. Association of factor expression levels with health-related quality of life and direct medical costs for people with haemophilia B. Journal Of Medical Economics 2022, 25: 386-392. PMID: 35253589, DOI: 10.1080/13696998.2022.2049552.
- Roberts J, Recht M, Gonzales S, Stanley J, Denne M, Caicedo J, Rockwood K. Incorporating the patient voice and patient engagement in GOAL‐Hēm: Advancing patient‐centric hemophilia care. Research And Practice In Thrombosis And Haemostasis 2022, 6: e12655. PMID: 35155975, PMCID: PMC8822263, DOI: 10.1002/rth2.12655.
- Burke T, Shaikh A, Ali T, Lickorish D, Li N, Curtis R, García-Diego D, Recht M, Sannié T, Skinner M, O'Hara J. POSC415 Economic and Health-Related Quality of Life Data across Baseline Fix Expression Levels in People with Haemophilia B: An Analysis Using the Factor Expression Study. Value In Health 2022, 25: s270. DOI: 10.1016/j.jval.2021.11.1316.
- Buckner T, Daoud N, Miles M, O'Neill C, Watson C, Recht M. Designing ATHN 7: Safety, effectiveness and practice of treatment of people with haemophilia in the United States through a natural history cohort study. The Journal Of Haemophilia Practice 2022, 9: 147-155. DOI: 10.2478/jhp-2022-0020.
- George L, Monahan P, Eyster M, Sullivan S, Ragni M, Croteau S, Rasko J, Recht M, Samelson-Jones B, MacDougall A, Jaworski K, Noble R, Curran M, Kuranda K, Mingozzi F, Chang T, Reape K, Anguela X, High K. Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A. New England Journal Of Medicine 2021, 385: 1961-1973. PMID: 34788507, PMCID: PMC8672712, DOI: 10.1056/nejmoa2104205.
- He C, Hinds D, Pezalla E, Cheng D, Chen E, Sammon J, Solari P, Recht M. Health insurance coverage and switching among people with hemophilia A in the United States. Journal Of Managed Care & Specialty Pharmacy 2021, 28: 232-243. PMID: 34780299, DOI: 10.18553/jmcp.2021.21311.
- Chandler M, Recht M, He C, Moulton T, Charafi L. Real-World Effectiveness of Damoctocog Alfa Pegol in the Subgroup of Adolescent Hemophilia A Patients Aged 12-18 Years in the ATHNdataset. Blood 2021, 138: 4241. DOI: 10.1182/blood-2021-152345.
- Witkop M, Recht M, DiMichele D, Mills K, Valentino L, Santaella M. National Hemophilia Foundation Convenes Diverse Community Voices to Define an Actionable National Research Blueprint for Inherited Bleeding Disorders. Blood 2021, 138: 4952. DOI: 10.1182/blood-2021-149518.
- Nolan B, Recht M, Rendo P, Falk A, Foster M, Casiano S, Rauch A, Shapiro A. Prophylaxis with rFIXFc Reduces the Frequency and Delays Time to First Spontaneous Bleed Event in Previously Untreated Patients with Hemophilia B: A Post Hoc Analysis of the PUPs B-LONG Trial. Blood 2021, 138: 498. DOI: 10.1182/blood-2021-148765.
- Messenger H, He C, Recht M, Kulkarni R. A Cross-Sectional Study of the American Thrombosis and Hemostasis Network Dataset for Outcomes of Dental Extractions in People with Hemophilia. Blood 2021, 138: 346. DOI: 10.1182/blood-2021-148498.
- Malec L, Hirsh N, O'Neill C, Watson C, Recht M. ATHN Transcends: A Natural History Cohort Study of the Safety, Effectiveness and Practice of Treatment in People with Non-Neoplastic Hematologic Disorders. Blood 2021, 138: 4242. DOI: 10.1182/blood-2021-148209.
- Santaella M, Witkop M, Mills K, Recht M, DiMichele D, Valentino L. National Hemophilia Foundation Enlists Diverse Patient Voices to Inform a National Research Blueprint for Inherited Bleeding Disorders. Blood 2021, 138: 1904. DOI: 10.1182/blood-2021-147857.
- Young G, Pipe S, Hermans C, Carcao M, Castaman G, Davis J, Ducore J, Dunn A, Escobar M, Journeycake J, Khan O, Mahlangu J, Meeks S, Mitha I, Négrier C, Nowak-Göttl U, Recht M, Chrisentery-Singleton T, Stasyshyn O, Vilchevska K, Martinez L, Wang M, Windyga J, Alexander W, Al-Sabbagh A, Bonzo D, Macie C, Mitchell I, Wilkinson T, Shapiro A. Eptacog Beta Efficacy in Children and Adolescents with Hemophilia A or B and Inhibitors: Subset Analysis Suggests Improved Caregiver Capacity to Assess Bleeding Episode Resolution with Subject Age. Blood 2021, 138: 3195. DOI: 10.1182/blood-2021-147434.
- Buckner T, Carpenter S, Daoud N, Hirsh N, McLean T, O'Neill C, Raffini L, Zia A, Recht M. Hemophilia Natural History Study (ATHN 7): Safety of Current Therapies for People with Hemophilia A or B. Blood 2021, 138: 2105. DOI: 10.1182/blood-2021-146726.
- Chrisentery-Singleton T, Alexander W, Al-Sabbagh A, Bonzo D, Callaghan M, Escobar M, Giermasz A, Hirsh N, Journeycake J, Nasr S, Quon D, Recht M. Athn 16: Safety of Coagulation Factor VIIa (recombinant)-Jncw for the Treatment of Bleeding Events in Patients with Congenital Hemophilia a or B with Inhibitors with or without Prophylactic Treatment. Blood 2021, 138: 3201. DOI: 10.1182/blood-2021-146247.
- Journeycake J, Cheng D, Chrisentery-Singleton T, Desai V, von Drygalski A, Fedor C, Hirsh N, Patel B, Raffini L, Recht M, Sidinio R, Wang M, Zhang X, Neufeld E. Reduced Dosing Frequency Following a Switch to Rix-FP for the Treatment of Hemophilia B: Results from the Athn 2 Study. Blood 2021, 138: 1039. DOI: 10.1182/blood-2021-144617.
- Veeranki S, Pednekar P, Graf M, Tuly R, Recht M, Batt K. A Delphi Consensus Approach for Difficult-to-Treat Patients with Severe Hemophilia A without Inhibitors. Journal Of Blood Medicine 2021, 12: 913-928. PMID: 34707422, PMCID: PMC8544791, DOI: 10.2147/jbm.s334852.
- Valentino L, Baker J, Butler R, Escobar M, Frick N, Karp S, Koulianos K, Lattimore S, Nugent D, Pugliese J, Recht M, Reding M, Rice M, Thibodeaux C, Skinner M. Integrated Hemophilia Patient Care via a National Network of Care Centers in the United States: A Model for Rare Coagulation Disorders. Journal Of Blood Medicine 2021, 12: 897-911. PMID: 34707421, PMCID: PMC8544265, DOI: 10.2147/jbm.s325031.
- Konkle B, Quon D, Raffini L, Recht M, Radulescu V, Carpenter S, Dunn A, Lu M, Watt M. A Prospective Observational Study of Antihemophilic Factor (Recombinant) Prophylaxis Related to Physical Activity Levels in Patients with Hemophilia A in the United States (SPACE). Journal Of Blood Medicine 2021, 12: 883-896. PMID: 34703348, PMCID: PMC8523903, DOI: 10.2147/jbm.s327180.
- Escobar M, Castaman G, Boix S, Callaghan M, de Moerloose P, Ducore J, Hermans C, Journeycake J, Leissinger C, Luck J, Mahlangu J, Miesbach W, Mitha I, Négrier C, Quon D, Recht M, Schved J, Shapiro A, Sidonio R, Srivastava A, Stasyshyn O, Vilchevska K, Wang M, Young G, Alexander W, Al‐Sabbagh A, Bonzo D, Macie C, Wilkinson T, Kessler C. The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors. Haemophilia 2021, 27: 921-931. PMID: 34636112, PMCID: PMC9292935, DOI: 10.1111/hae.14419.
- Garrison L, Pezalla E, Towse A, Yang H, Faust E, Wu E, Li N, Sawyer E, Recht M. Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations. Value In Health 2021, 24: 1628-1633. PMID: 34711363, DOI: 10.1016/j.jval.2021.05.008.
- Witkop M, Morgan G, O'Hara J, Recht M, Buckner T, Nugent D, Curtis R, O'Mahony B, Skinner M, Mulhern B, Cawson M, Ali T, Sawyer E, Li N. Patient preferences and priorities for haemophilia gene therapy in the US: A discrete choice experiment. Haemophilia 2021, 27: 769-782. PMID: 34310811, PMCID: PMC9290457, DOI: 10.1111/hae.14383.
- Nolan B, Klukowska A, Shapiro A, Rauch A, Recht M, Ragni M, Curtin J, Gunawardena S, Mukhopadhyay S, Jayawardene D, Winding B, Fischer K, Liesner R. Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B. Blood Advances 2021, 5: 2732-2739. PMID: 34242387, PMCID: PMC8288672, DOI: 10.1182/bloodadvances.2020004085.
- Miesbach W, Giermasz A, Castaman G, Key N, Lattimore S, Leebeek F, von Drygalski A, Recht M, Gomez E, Gut R, Pipe S. Gene Transfer with Etranacogene dezaparvovec (AAV5-Padua hFIX variant) in Adults with Severe or Moderate-Severe Hemophilia B: Two Year Data from a Phase 2b Trial. Hämostaseologie 2021, 41: s6. DOI: 10.1055/s-0041-1728090.
- Sampson M, Cheng D, Recht M, Fargo J. The effect of age at diagnosis of type 1 von Willebrand disease on diagnostic laboratory values: A paediatric perspective. Haemophilia 2021, 27: e412-e414. PMID: 33533138, DOI: 10.1111/hae.14265.
- Li N, Sawyer E, Maruszczyk K, Guzauskas G, Slomka M, Burke T, Martin A, O’Hara J, Stevenson M, Recht M. Adult lifetime cost of hemophilia B management in the US: payer and societal perspectives from a decision analytic model. Journal Of Medical Economics 2021, 24: 363-372. PMID: 33591884, DOI: 10.1080/13696998.2021.1891088.
- Witkop M, Wang M, Hernandez G, Recht M, Baumann K, Cooper D. Impact of haemophilia on patients with mild‐to‐moderate disease: Results from the P‐FiQ and B‐HERO‐S studies. Haemophilia 2021, 27: 8-16. PMID: 33522654, DOI: 10.1111/hae.14251.
- Recht M. Safety first: Tracking adverse events associated with new therapies for people with hemophilia. Journal Of Thrombosis And Haemostasis 2021, 19: 3-5. PMID: 33331044, DOI: 10.1111/jth.15188.
- Reipert B, Gangadharan B, Hofbauer C, Berg V, Schweiger H, Bowen J, Blatny J, Fijnvandraat K, Mullins E, Klintman J, Male C, McGuinn C, Meeks S, Radulescu V, Ragni M, Recht M, Shapiro A, Staber J, Yaish H, Santagostino E, Brown D. The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development. Blood Advances 2020, 4: 5785-5796. PMID: 33232473, PMCID: PMC7686884, DOI: 10.1182/bloodadvances.2020002731.
- von Drygalski A, Giermasz A, Castaman G, Key N, Lattimore S, Leebeek F, Miesbach W, Recht M, Gomez E, Gut R, Pipe S. Etranacogene Dezaparvovec (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B: Two Year Data from a Phase 2b Trial. Blood 2020, 136: 13. DOI: 10.1182/blood-2020-139295.
- Buckner T, Carpenter S, Croteau S, Cuker A, Daoud N, Kempton C, Malec L, McLean T, Raffini L, Staber J, Wang M, Watson C, Zia A, Recht M. Hemophilia Natural History Study (ATHN 7): Baseline Characteristics, Adverse Events, and Self-Reported Health Status of Individuals with Hemophilia a and B. Blood 2020, 136: 2-3. DOI: 10.1182/blood-2020-137696.
- Johnsen J, Fletcher S, Dove A, McCracken H, Martin B, Kircher M, Josephson N, Shendure J, Ruuska S, Valentino L, Pierce G, Watson C, Cheng D, Recht M, Konkle B. Results of Genetic Analysis of 11,341 Participants Enrolled in the My Life, Our Future (MLOF) Hemophilia Genotyping Initiative. Blood 2020, 136: 19. DOI: 10.1182/blood-2020-140649.
- Journeycake J, Recht M, Guelcher C, Neufeld E, Ragni M, Sidonio R, Takemoto C, Tarantino M, Cheng D, Lattimore S, Caicedo J, Denne M. Dosing, Patient Satisfaction and Other Patient-Reported Outcomes after Switching to Rurioctocog Alfa Pegol in Athn 2: A Longitudinal, Observational Study of Previously Treated Hemophilia Patients Switching Coagulation Replacement Factor Products. Blood 2020, 136: 17-18. DOI: 10.1182/blood-2020-138898.
- Pipe S, Recht M, Callaghan M, Sidonio R, Grandoni J, Duretz V, Bonzo D, Plantier J, Evans S, Mitchell I, Hermans C. In Vitro Evaluation of Thrombin Generation of Eptacog Beta (Factor VIIa, Recombinant) and Emicizumab in Congenital Hemophilia Α Plasma with and without Inhibitors. Blood 2020, 136: 41-42. DOI: 10.1182/blood-2020-136430.
- Lim M, Cheng D, Recht M, Kempton C, Key N. Management of inhibitors in persons with non‐severe hemophilia A in the United States. American Journal Of Hematology 2020, 96: e9-e11. PMID: 32976635, DOI: 10.1002/ajh.26011.
- Lim M, Cheng D, Recht M, Kempton C, Key N. Inhibitors and mortality in persons with nonsevere hemophilia A in the United States. Blood Advances 2020, 4: 4739-4747. PMID: 33007074, PMCID: PMC7556148, DOI: 10.1182/bloodadvances.2020002626.
- Goldscheitter G, Recht M, Sochacki P, Manco‐Johnson M, Taylor J. Biomarkers of bone disease in persons with haemophilia. Haemophilia 2020, 27: 149-155. PMID: 32856388, DOI: 10.1111/hae.13986.
- Ahuja S, Recht M, Konkle B. Hemostatic Therapies for Heavy Menstrual Bleeding. 2020, 119-127. DOI: 10.1007/978-3-030-48446-0_11.
- Malec L, Cheng D, Witmer C, Jaffray J, Kouides P, Haley K, Sidonio R, Johnson K, Recht M, White G, Croteau S, Ragni M. The impact of extended half‐life factor concentrates on prophylaxis for severe hemophilia in the United States. American Journal Of Hematology 2020, 95: 960-965. PMID: 32356313, DOI: 10.1002/ajh.25844.
- Wang M, Recht M, Iyer N, Cooper D, Soucie J. Hemophilia without prophylaxis: Assessment of joint range of motion and factor activity. Research And Practice In Thrombosis And Haemostasis 2020, 4: e12347. PMID: 32864554, PMCID: PMC7443428, DOI: 10.1002/rth2.12347.
- Marshall A, Recht M, Sridharan M, Nichols W, Ashrani A, Fischer K, Miles M, Riedel A, Pruthi R. A study of dedicated haemophilia carrier clinics in the United States: Prevalence, services offered and barriers to development. Haemophilia 2020, 26: e253-e255. PMID: 32537802, DOI: 10.1111/hae.14071.
- Warren B, Thornhill D, Stein J, Fadell M, Ingram J, Funk S, Norton K, Lane H, Bennett C, Dunn A, Recht M, Shapiro A, Manco-Johnson M. Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study. Blood Advances 2020, 4: 2451-2459. PMID: 32492157, PMCID: PMC7284094, DOI: 10.1182/bloodadvances.2019001311.
- Konkle B, Recht M, Hilger A, Marks P. The critical need for postmarketing surveillance in gene therapy for haemophilia. Haemophilia 2020, 27: 126-131. PMID: 32495492, DOI: 10.1111/hae.13972.
- Buckner T, Watson C, Recht M. Emicizumab in Hemophilia A. New England Journal Of Medicine 2020, 382: 785-786. PMID: 32074441, DOI: 10.1056/nejmc1916299.
- Haley K, Sidonio R, Abraham S, Cheng D, Recht M, Kulkarni R. A Cross-Sectional Study of Women and Girls with Congenital Bleeding Disorders: The American Thrombosis and Hemostasis Network Cohort. Journal Of Women's Health 2020, 29: 670-676. PMID: 31905045, DOI: 10.1089/jwh.2019.7930.
- Pipe S, Giermasz A, Castaman G, Key N, Lattimore S, Leebeek F, Miesbach W, Recht M, Gomez E, Long A, Gut R, von Drygalski A. One Year Data from a Phase 2b Trial of AMT-061 (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B. Blood 2019, 134: 3348. DOI: 10.1182/blood-2019-128765.
- Von Drygalski A, Giermasz A, Castaman G, Key N, Lattimore S, Leebeek F, Miesbach W, Recht M, Long A, Gut R, Sawyer E, Pipe S. Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B. Blood Advances 2019, 3: 3241-3247. PMID: 31698454, PMCID: PMC6855101, DOI: 10.1182/bloodadvances.2019000811.
- Konkle B, Recht M, Group T. The national blueprint for 21st century data and specimen collection and observational cohort studies: NHLBI State of the Science Workshop on factor VIII inhibitors. Haemophilia 2019, 25: 590-594. PMID: 31329362, DOI: 10.1111/hae.13772.
- Warren B, Jacobson L, Kempton C, Buchanan G, Recht M, Brown D, Leissinger C, Shapiro A, Abshire T, Manco‐Johnson M, Investigators F. Factor VIII prophylaxis effects outweigh other hemostasis contributors in predicting severe haemophilia A joint outcomes. Haemophilia 2019, 25: 867-875. PMID: 31115111, PMCID: PMC7273872, DOI: 10.1111/hae.13778.
- Mahlangu J, Oldenburg J, Callaghan M, Shima M, Mancuso M, Trask P, Recht M, Garcia C, Yang R, Lehle M, Macharia H, Asikanius E, Levy G, Kruse‐Jarres R, von Mackensen S. Health‐related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non‐interventional study (NIS). Haemophilia 2019, 25: 382-391. PMID: 31016855, PMCID: PMC6850115, DOI: 10.1111/hae.13731.
- Aledort L, Carpenter S, Cuker A, Kulkarni R, Recht M, Young G, Leissinger C. Why plasma‐derived factor VIII? Haemophilia 2019, 25: e183-e185. PMID: 30866124, DOI: 10.1111/hae.13705.
- Samuelson Bannow B, Recht M, Négrier C, Hermans C, Berntorp E, Eichler H, Mancuso M, Klamroth R, O'Hara J, Santagostino E, Matsushita T, Kessler C. Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis. Blood Reviews 2019, 35: 43-50. PMID: 30922616, DOI: 10.1016/j.blre.2019.03.002.
- Miesbach W, Castaman G, Key N, Lattimore S, Leebeek F, Von Drygalski A, Zelenkofske S, Recht M, Pipe S. Phase 2b Trial of AMT-061 (AAV5-Padua hFIX): Translation into Humans of an Enhanced Gene Transfer Vector for Adults with Severe or Moderate-severe Hemophilia B. Hämostaseologie 2019, 39: s1-s92. DOI: 10.1055/s-0039-1680141.
- Miesbach W, Castaman G, Key N, Lattimore S, Leebeek F, Zelenkofske S, Recht M, Pipe S. HOPE-B: Study Design of a Phase III trial of an Investigational Gene Therapy AMT-061 in Subjects with Severe or Moderately Severe Hemophilia B. Hämostaseologie 2019, 39: s1-s92. DOI: 10.1055/s-0039-1680217.
- Winsnes K, Sochacki P, Eriksson C, Shereck E, Recht M, Johnson K, De Mola R, Stork L. Delirium in the pediatric hematology, oncology, and bone marrow transplant population. Pediatric Blood & Cancer 2019, 66: e27640. PMID: 30697919, DOI: 10.1002/pbc.27640.
- Warren B, Thornhill D, Stein J, Fadell M, Funk S, Lane H, Bennett C, Shapiro A, Recht M, Manco-Johnson M. Early Prophylaxis Provides Continued Joint Protection in Severe Hemophilia A: Results of the Joint Outcome Continuation Study. Blood 2018, 132: 382. DOI: 10.1182/blood-2018-99-117413.
- Nathwani A, Reiss U, Tuddenham E, Chowdary P, McIntosh J, Riddell A, Pie J, Mahlangu J, Recht M, Shen Y, Halka K, Meagher M, Nienhuis A, Davidoff A, Mangles S, Morton C, Junfang Z, Radulescu V. Adeno-Associated Mediated Gene Transfer for Hemophilia B:8 Year Follow up and Impact of Removing “Empty Viral Particles” on Safety and Efficacy of Gene Transfer. Blood 2018, 132: 491. DOI: 10.1182/blood-2018-99-118334.
- Gangadharan B, Reipert B, Berg V, Scheiflinger F, Blatny J, Fijnvandraat K, Gruppo R, Klintman J, Male C, McGuinn C, Meeks S, Radulescu V, Ragni M, Recht M, Santagostino E, Shapiro A, Staber J, Yaish H, Yee D, Brown D. Data Coming out of the Human Inhibitor PUP Study (HIPS) Reveal 4 Subgroups of Patients with Distinct Antibody Signatures. Blood 2018, 132: 3774. DOI: 10.1182/blood-2018-99-115979.
- Mahlangu J, Oldenburg J, Callaghan M, Shima M, Santagostino E, Moore M, Recht M, Garcia C, Yang R, Lehle M, Macharia H, Asikanius E, Levy G, Kruse‐Jarres R. Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multi‐centre, non‐interventional study. Haemophilia 2018, 24: 921-929. PMID: 30295389, DOI: 10.1111/hae.13612.
- Croteau S, Callaghan M, Davis J, Dunn A, Guerrera M, Khan O, Neufeld E, Raffini L, Recht M, Wang M, Iorio A. Focusing in on use of pharmacokinetic profiles in routine hemophilia care. Research And Practice In Thrombosis And Haemostasis 2018, 2: e12118. PMID: 30046766, PMCID: PMC6046597, DOI: 10.1002/rth2.12118.
- Manco‐Johnson M, Byams V, Recht M, Dudley B, Dupervil B, Aschman D, Oakley M, Kapica S, Voutsis M, Humes S, Kulkarni R, Grant A, Network. O. Community counts: Evolution of a national surveillance system for bleeding disorders. American Journal Of Hematology 2018, 93: e137-e140. PMID: 29473207, PMCID: PMC6145085, DOI: 10.1002/ajh.25076.
- Roberts J, Lattimore S, Recht M, Jackson S, Gue D, Squire S, Robinson K, Price V, Denne M, Richardson S, Rockwood K. Goal Attainment Scaling for haemophilia (GAS‐Hēm): testing the feasibility of a new patient‐centric outcome measure in people with haemophilia. Haemophilia 2018, 24: e199-e206. PMID: 29626387, DOI: 10.1111/hae.13454.
- Batt K, Boggio L, Neff A, Buckner T, Wang M, Quon D, Witkop M, Recht M, Kessler C, Iyer N, Cooper D. Patient‐reported outcomes and joint status across subgroups of US adults with hemophilia with varying characteristics: Results from the Pain, Functional Impairment, and Quality of Life (P‐FiQ) study. European Journal Of Haematology 2018, 100: 14-24. PMID: 29498783, DOI: 10.1111/ejh.13028.
- Buckner T, Batt K, Quon D, Witkop M, Recht M, Kessler C, Baumann K, Hernandez G, Wang M, Cooper D, Kempton C. Assessments of pain, functional impairment, anxiety, and depression in US adults with hemophilia across patient‐reported outcome instruments in the Pain, Functional Impairment, and Quality of Life (P‐FiQ) study. European Journal Of Haematology 2018, 100: 5-13. PMID: 29498784, DOI: 10.1111/ejh.13027.
- Rocheleau A, Khader A, Ngo A, Boehnlein C, McDavitt C, Lattimore S, Recht M, McCarty O, Haley K. Pilot study of novel lab methodology and testing of platelet function in adolescent women with heavy menstrual bleeding. Pediatric Research 2018, 83: 693-701. PMID: 29166373, PMCID: PMC5902421, DOI: 10.1038/pr.2017.298.
- Kempton C, Recht M, Neff A, Wang M, Buckner T, Soni A, Quon D, Witkop M, Boggio L, Gut R, Cooper D. Impact of pain and functional impairment in US adults with haemophilia: Patient‐reported outcomes and musculoskeletal evaluation in the pain, functional impairment and quality of life (P‐FiQ) study. Haemophilia 2017, 24: 261-270. PMID: 29218759, DOI: 10.1111/hae.13377.
- Kruse-Jarres R, Callaghan M, Croteau S, Jimenez-Yuste V, Khoo L, Liesner R, Matsushita T, Recht M, Young G, Chang T, Dhalluin C, Mu Y, Xu J, Devenport J, Ko R, Solari P, Oldenburg J. Surgical Experience in Two Multicenter, Open-Label Phase 3 Studies of Emicizumab in Persons with Hemophilia A with Inhibitors (HAVEN 1 and HAVEN 2). Blood 2017, 130: 89. DOI: 10.1182/blood.v130.suppl_1.89.89.
- Gangadharan B, Reipert B, Scheiflinger F, Bowen J, Donnachie E, van Draat K, Gruppo R, Klintman J, Male C, McGuinn C, Meeks S, Recht M, Ragni M, Yaish H, Shapiro A, Yee D, Radulescu V, Santagostino E, Brown D. Longitudinal Antibody Signatures Following FVIII Replacement Therapy in Previously Untreated Patients with Severe Hemophilia Α- New Insights from the Hemophilia Inhibitor PUP Study (HIPS). Blood 2017, 130: 88. DOI: 10.1182/blood.v130.suppl_1.88.88.
- Wang M, Recht M, Iyer N, Cooper D, Soucie J. The Relationship of Joint Range of Motion to Factor Activity in Patients with Hemophilia A and B without Prophylaxis: A Longitudinal Assessment of the CDC-UDC Hemophilia Dataset. Blood 2017, 130: 756. DOI: 10.1182/blood.v130.suppl_1.756.756.
- Kempton C, Wang M, Recht M, Neff A, Shapiro A, Soni A, Kulkarni R, Buckner T, Batt K, Iyer N, Cooper D. Reliability of patient-reported outcome instruments in US adults with hemophilia: the Pain, Functional Impairment and Quality of life (P-FiQ) study. Patient Preference And Adherence 2017, 11: 1603-1612. PMID: 29033549, PMCID: PMC5614789, DOI: 10.2147/ppa.s141389.
- Batt K, Recht M, Cooper D, Iyer N, Kempton C. Construct validity of patient-reported outcome instruments in US adults with hemophilia: results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study. Patient Preference And Adherence 2017, 11: 1369-1380. PMID: 28860720, PMCID: PMC5558590, DOI: 10.2147/ppa.s141390.
- Ullman M, Zhang Q, Grosse S, Recht M, Soucie J, Investigators T. Prophylaxis use among males with haemophilia B in the United States. Haemophilia 2017, 23: 910-917. PMID: 28780772, PMCID: PMC5724962, DOI: 10.1111/hae.13317.
- Shatzel J, Azar S, Scherber R, Gay N, Deloughery T, VanSandt A, Kruse‐Jarres R, Recht M, Taylor J. Unexpected pharmacokinetics of recombinant porcine factor VIII in a patient with acquired factor VIII deficiency and spontaneous epidural haematoma. Haemophilia 2017, 23: e453-e456. PMID: 28664642, DOI: 10.1111/hae.13247.
- Kahan S, Cuker A, Kushner R, Maahs J, Recht M, Wadden T, Willis T, Majumdar S, Ungar D, Cooper D. Prevalence and impact of obesity in people with haemophilia: Review of literature and expert discussion around implementing weight management guidelines. Haemophilia 2017, 23: 812-820. PMID: 28636076, DOI: 10.1111/hae.13291.
- Recht M, Rajpurkar M, Chitlur M, d'Oiron R, Zotz R, Di Minno G, Cooper D, Poon M. Independent adjudicator assessments of platelet refractoriness and rFVIIa efficacy in bleeding episodes and surgeries from the multinational Glanzmann's thrombasthenia registry. American Journal Of Hematology 2017, 92: 646-652. PMID: 28370369, DOI: 10.1002/ajh.24741.
- Witkop M, Neff A, Buckner T, Wang M, Batt K, Kessler C, Quon D, Boggio L, Recht M, Baumann K, Gut R, Cooper D, Kempton C. Self‐reported prevalence, description and management of pain in adults with haemophilia: methods, demographics and results from the Pain, Functional Impairment, and Quality of life (P‐FiQ) study. Haemophilia 2017, 23: 556-565. PMID: 28419637, DOI: 10.1111/hae.13214.
- Chitlur M, Rajpurkar M, Recht M, Tarantino M, Yee D, Cooper D, Gunawardena S. Recognition and management of platelet-refractory bleeding in patients with Glanzmann’s thrombasthenia and other severe platelet function disorders. International Journal Of General Medicine 2017, 10: 95-99. PMID: 28435309, PMCID: PMC5388206, DOI: 10.2147/ijgm.s128953.
- Buckner T, Witkop M, Guelcher C, Frey M, Hunter S, Peltier S, Recht M, Walsh C, Kessler C, Owens W, Clark D, Frick N, Rice M, Iyer N, Holot N, Cooper D, Sidonio R. Management of US men, women, and children with hemophilia and methods and demographics of the Bridging Hemophilia B Experiences, Results and Opportunities into Solutions (B‐HERO‐S) study. European Journal Of Haematology 2017, 98: 5-17. PMID: 28319338, DOI: 10.1111/ejh.12854.
- Oleson D, Fox L, Nguyen T, Sochacki P, McCarthy M, Adams E, Recht M. A comparison of two types of ankle supports in men with haemophilia and unilateral ankle pain from arthropathy. Haemophilia 2017, 23: 444-448. PMID: 28220573, DOI: 10.1111/hae.13184.
- Recht M, Chitlur M, Lam D, Sarnaik S, Rajpurkar M, Cooper D, Gunawardena S. Epistaxis as a Common Presenting Symptom of Glanzmann’s Thrombasthenia, a Rare Qualitative Platelet Disorder: Illustrative Case Examples. Case Reports In Emergency Medicine 2017, 2017: 8796425. PMID: 28299211, PMCID: PMC5337314, DOI: 10.1155/2017/8796425.
- Mahlangu J, Oldenburg J, Callaghan M, Shima M, Santagostino E, Lehle M, Uguen M, Hirst C, Moore M, Recht M, Garcia C, Yang R, Kruse-Jarres R. Bleeding Events and Safety Outcomes in Patients with Hemophilia a with Inhibitors: A Prospective, Multicenter, Non-Interventional Study. Blood 2016, 128: 3800. DOI: 10.1182/blood.v128.22.3800.3800.
- Batt K, Recht M, Wang M, Quon D, Boggio L, Kessler C, Buckner T, Neff A, Iyer N, Cooper D, Kempton C. Linear and Logistic Regression Models of Patient-Reported Outcomes and Patient Characteristics in US Adults with Hemophilia from the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study. Blood 2016, 128: 252. DOI: 10.1182/blood.v128.22.252.252.
- Haley K, Lattimore S, McDavitt C, Khader A, Boehnlein C, Baker-Groberg S, Ngo A, McCarty O, Recht M. Identification of Qualitative Platelet Disorders in Adolescent Women with Heavy Menstrual Bleeding. Blood 2016, 128: 4922. DOI: 10.1182/blood.v128.22.4922.4922.
- Janic D, Matytsina I, Misgav M, Oldenburg J, Ozelo M, Recht M, Korsholm L, Savic A, Santagostino E. Safety and Efficacy of Turoctocog Alfa in Prevention and on-Demand Treatment of Bleeding Episodes in Patients with Hemophilia A. Blood 2016, 128: 3790. DOI: 10.1182/blood.v128.22.3790.3790.
- Reipert B, Gangadharan B, Hofbauer C, Scheiflinger F, Bowen J, Donnachie E, Fijvandraat K, Gruppo R, Klintman J, Male C, McGuinn C, Meeks S, Recht M, Ragni M, Yaish H, Santagostino E, Brown D. Appearance of High-Affinity Antibodies Precedes Clinical Diagnosis of FVIII Inhibitors - Preliminary Analysis from the Hemophilia Inhibitor PUP Study (HIPS). Blood 2016, 128: 328. DOI: 10.1182/blood.v128.22.328.328.
- Aledort L, Recht M, Kulkarni R, Kobrinsky N. Adult, previously untreated patients remain a significant therapeutic challenge. Journal Of Thrombosis And Haemostasis 2016, 14: 2075-2076. PMID: 27496600, DOI: 10.1111/jth.13434.
- Recht M, Konkle B, Jackson S, Neufeld E, Rockwood K, Pipe S. Recognizing the need for personalization of haemophilia patient‐reported outcomes in the prophylaxis era. Haemophilia 2016, 22: 825-832. PMID: 27581872, DOI: 10.1111/hae.13066.
- Lentz S, Cerqueira M, Janic D, Kempton C, Matytsina I, Misgav M, Oldenburg J, Ozelo M, Recht M, Rosholm A, Savic A, Suzuki T, Tiede A, Santagostino E. Interim results from a large multinational extension trial (guardian™2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A. Haemophilia 2016, 22: e445-e449. PMID: 27291066, DOI: 10.1111/hae.12990.
- Batt K, Recht M, Cooper D, Iyer N, Kempton C. PRM123 CONSTRUCT VALIDITY OF PATIENT-REPORTED OUTCOME INSTRUMENTS IN US ADULT PEOPLE WITH HEMOPHILIA (PWH): RESULTS FROM THE PAIN, FUNCTIONAL IMPAIRMENT, AND QUALITY OF LIFE (P-FIQ) STUDY. Value In Health 2016, 19: a93. DOI: 10.1016/j.jval.2016.03.1737.
- Baker‐Groberg S, Lattimore S, Recht M, McCarty O, Haley K. Assessment of neonatal platelet adhesion, activation, and aggregation. Journal Of Thrombosis And Haemostasis 2016, 14: 815-827. PMID: 26806373, PMCID: PMC4828266, DOI: 10.1111/jth.13270.
- Despotovic J, Polfus L, Flanagan J, Bennett C, Lambert M, Neunert C, Kumar M, Klaassen R, Thornburg C, Jeng M, Recht M, Kirk S, Thompson A, Nugent D, Neufeld E, Bussel J, Boerwinkle E, Grace R. Genes Influencing the Development and Severity of Chronic ITP Identified through Whole Exome Sequencing. Blood 2015, 126: 73. DOI: 10.1182/blood.v126.23.73.73.
- Warren B, Jacobsen L, Villalobos-Menuey E, Abshire T, Shapiro A, Recht M, Brown D, Leissinger C, Kempton C, Lane H, Nugent D, Manco-Johnson M. Non-Factor VIII Coagulation Proteins Fail to Predict Joint Outcome in Severe Hemophilia a. Blood 2015, 126: 2289. DOI: 10.1182/blood.v126.23.2289.2289.
- Shatzel J, Azar S, Gay N, Luo J, Deloughery T, Recht M, Taylor J. The Clinical Associations and Outcomes of Patients Admitted with Acquired Hemophilia; A Review of the 2012 National Inpatient Sample. Blood 2015, 126: 1091. DOI: 10.1182/blood.v126.23.1091.1091.
- Kempton C, Recht M, Neff A, Wang M, Buckner T, Soni A, Quon D, Witkop M, Boggio L, Cooper D. Impact of Pain and Functional Impairment in US Adult People with Hemophilia (PWH): Patient-Reported Outcomes and Musculoskeletal Evaluation in the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study. Blood 2015, 126: 39. DOI: 10.1182/blood.v126.23.39.39.
- Mahlangu J, Weldingh K, Lentz S, Kaicker S, Karim F, Matsushita T, Recht M, Tomczak W, Windyga J, Ehrenforth S, Knobe K, Investigators F, Weltermann A, de Paula E, Cerqueira M, Zupancic‐Salek S, Katsarou O, Economou M, Nemes L, Boda Z, Santagostino E, Tagariello G, Hanabusa H, Fukutake K, Shima M, Serban M, Elezovic I, Savic A, Shen M, Chuansumrit A, Angchaisuksiri P, Kavakli K, Sasmaz I, Madan B, Giangrande P, Kempton C, Young G, Quon D, Ameri A, Kuriakose P, Obzut D, Wang M, Ortiz I. Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity. Journal Of Thrombosis And Haemostasis 2015, 13: 1989-1998. PMID: 26362483, DOI: 10.1111/jth.13141.
- Kempton C, Wang M, Recht M, Neff A, Shapiro A, Buckner T, Kulkarni R, Nugent D, Batt K, Wisniewski T, Cooper D. PSY58 Pain Functional Impairment and Quality of Life (P-FIQ): an assessment of reliability of five patient reported outcome (PRO) instruments in Adult People with Hemophilia (PWH). Value In Health 2015, 18: a301-a302. DOI: 10.1016/j.jval.2015.03.1756.
- Gay N, Lee S, Liel M, Sochacki P, Recht M, Taylor J. Increased fracture rates in people with haemophilia: a 10‐year single institution retrospective analysis. British Journal Of Haematology 2015, 170: 584-586. PMID: 25659575, DOI: 10.1111/bjh.13312.
- Haley K, Friedman K, Recht M. A Retrospective Analysis of Bleeding Phenotype and Von Willebrand Factor Exon 28 Polymorphism D1472H at a Single Institution. Blood 2014, 124: 2849. DOI: 10.1182/blood.v124.21.2849.2849.
- Larson E, Iwaniec U, Holmgren S, Turner R, Recht M, Taylor J. Age-Associated Bone Disease in Factor VIII-Deficient Mice. Blood 2014, 124: 2798. DOI: 10.1182/blood.v124.21.2798.2798.
- Recht M, Rajpurkar M, Chitlur M, Reding M, Frey M, Peltier S, Guelcher C, Stephens D, Cooper D. Impact of Glanzmann’s Thrombasthenia (GT): Perceptions from US Patients and Parents. Blood 2014, 124: 4853. DOI: 10.1182/blood.v124.21.4853.4853.
- Chitlur M, Recht M, Rajpurkar M, Neufeld E, Kessler C, Reding M, Tarantino M, Cooper D. Unmet Needs in Diagnosis and Treatment of Glanzmann’s Thrombasthenia (GT): Perceptions of US Hematologists and Nurses. Blood 2014, 124: 2179. DOI: 10.1182/blood.v124.21.2179.2179.
- Recht M, Lentz S, Zupancic-Šalek S, Matytsina I, Landorph A, Saugstrup T. Factor VIII Dosing and Preventive Efficacy in Obese Patients with Hemophilia (BMI ≥30 kg/m2) – a Post-Hoc Sub-Analysis of the guardian™ Trials. Blood 2014, 124: 1503. DOI: 10.1182/blood.v124.21.1503.1503.
- Maahs J, Donkin J, Recht M, Cooper D. Mixing and administration times of bypassing agents: observations from the Dosing Observational Study in Hemophilia (DOSE). Journal Of Blood Medicine 2014, 5: 153-156. PMID: 25187744, PMCID: PMC4149444, DOI: 10.2147/jbm.s61859.
- Recht M, Neufeld E, Sharma V, Solem C, Pickard A, Gut R, Cooper D. Impact of Acute Bleeding on Daily Activities of Patients with Congenital Hemophilia with Inhibitors and Their Caregivers and Families: Observations from the Dosing Observational Study in Hemophilia (DOSE). Value In Health 2014, 17: 744-748. PMID: 25236999, DOI: 10.1016/j.jval.2014.07.003.
- Rajpurkar M, Chitlur M, Recht M, Cooper D. Use of recombinant activated factor VII in patients with Glanzmann's thrombasthenia: a review of the literature. Haemophilia 2014, 20: 464-471. PMID: 24948404, DOI: 10.1111/hae.12473.
- Haley K, Recht M, McCarty O. Neonatal platelets: mediators of primary hemostasis in the developing hemostatic system. Pediatric Research 2014, 76: 230-237. PMID: 24941213, PMCID: PMC4348010, DOI: 10.1038/pr.2014.87.
- Haley K, Russell T, Boshkov L, Leger R, Garratty G, Recht M, Nazemi K. Fatal carboplatin-induced immune hemolytic anemia in a child with a brain tumor. Journal Of Blood Medicine 2014, 5: 55-58. PMID: 24868179, PMCID: PMC4031206, DOI: 10.2147/jbm.s59192.
- Adams E, Gloeckner S, Stadler D, Black A, Helm J, Recht M. Food insecurity is associated with household insurance status and number of affected children among families of children with hemophilia (805.14). The FASEB Journal 2014, 28 DOI: 10.1096/fasebj.28.1_supplement.805.14.
- Adams E, Deutsche J, Okoroh E, Owens‐McAlister S, Majumdar S, Ullman M, Damiano M, Recht M, Group T. An inventory of healthy weight practices in federally funded haemophilia treatment centres in the United States. Haemophilia 2014, 20: 639-643. PMID: 24629074, PMCID: PMC4484574, DOI: 10.1111/hae.12385.
- Haley K, Recht M, McCarty O. Development Of a Novel Method To Assess Neonatal Platelet Function. Blood 2013, 122: 4740. DOI: 10.1182/blood.v122.21.4740.4740.
- Manco-Johnson M, Manco-Johnson M, Blades T, Funk S, Lane H, McRedmond K, Dunn A, Recht M, Shapiro A, Valentino L, Brown D. Long-Term Orthopedic Effects Of Delaying Prophylaxis In Severe Hemophilia A Until Age 6 Years: Results Of The Joint Outcome Study Continuation (JOSc). Blood 2013, 122: 210. DOI: 10.1182/blood.v122.21.210.210.
- Recht M, Carly P, Larson E, Manco-Johnson M, Taylor J. Biomarkers Of Bone Disease In Subjects With Hemophilia. Blood 2013, 122: 1113. DOI: 10.1182/blood.v122.21.1113.1113.
- Recht M, Liel M, Turner R, Klein R, Taylor J. The bone disease associated with factor VIII deficiency in mice is secondary to increased bone resorption. Haemophilia 2013, 19: 908-912. PMID: 23731369, DOI: 10.1111/hae.12195.
- Soucie J, Monahan P, Kulkarni R, De Staercke C, Recht M, Chitlur M, Gruppo R, Hooper W, Kessler C, Manco‐Johnson M, Powell J, Pyle M, Riske B, Sabio H, Trimble S. Evidence for the continued transmission of parvovirus B19 in patients with bleeding disorders treated with plasma‐derived factor concentrates. Transfusion 2013, 53: 1143-1144. PMID: 23659532, DOI: 10.1111/trf.12153.
- Lentz S, Misgav M, Ozelo M, Šalek S, Veljkovic D, Recht M, Cerqueira M, Tiede A, Brand B, Mancuso M, Seremetis S, Lindblom A, Martinowitz U. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy. Haemophilia 2013, 19: 691-697. PMID: 23647704, DOI: 10.1111/hae.12159.
- Lane J, McLaren P, Dorrell L, Shianna K, Stemke A, Pelak K, Moore S, Oldenburg J, Alvarez-Roman M, Angelillo-Scherrer A, Boehlen F, Bolton-Maggs P, Brand B, Brown D, Chiang E, Cid-Haro A, Clotet B, Collins P, Colombo S, Dalmau J, Fogarty P, Giangrande P, Gringeri A, Iyer R, Katsarou O, Kempton C, Kuriakose P, Lin J, Makris M, Manco-Johnson M, Tsakiris D, Martinez-Picado J, Mauser-Bunschoten E, Neff A, Oka S, Oyesiku L, Parra R, Peter-Salonen K, Powell J, Recht M, Shapiro A, Stine K, Talks K, Telenti A, Wilde J, Yee T, Wolinsky S, Martinson J, Hussain S, Bream J, Jacobson L, Carrington M, Goedert J, Haynes B, McMichael A, Goldstein D, Fellay J, Immunology F. A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A. Human Molecular Genetics 2013, 22: 1903-1910. PMID: 23372042, PMCID: PMC3613165, DOI: 10.1093/hmg/ddt033.
- Soucie J, De Staercke C, Monahan P, Recht M, Chitlur M, Gruppo R, Hooper W, Kessler C, Kulkarni R, Manco‐Johnson M, Powell J, Pyle M, Riske B, Sabio H, Trimble S, Network H. Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma‐derived factor concentrates in the era of nucleic acid test screening. Transfusion 2012, 53: 1217-1225. PMID: 22998193, PMCID: PMC4519820, DOI: 10.1111/j.1537-2995.2012.03907.x.
- Neufeld E, Recht M, Sabio H, Saxena K, Solem C, Pickard A, Gut R, Cooper D. Effect of Acute Bleeding on Daily Quality of Life Assessments in Patients with Congenital Hemophilia with Inhibitors and Their Families: Observations from the Dosing Observational Study in Hemophilia. Value In Health 2012, 15: 916-925. PMID: 22999142, DOI: 10.1016/j.jval.2012.05.005.
- Auerswald G, Thompson A, Recht M, Brown D, Liesner R, Guzmán-Becerra N, Dyck-Jones J, Ewenstein B, Abbuehl B. Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A. Thrombosis And Haemostasis 2012, 107: 1072-1082. PMID: 22476554, PMCID: PMC6292131, DOI: 10.1160/th11-09-0642.
- Liel M, Greenberg D, Recht M, Vanek C, Klein R, Taylor J. Decreased bone density and bone strength in a mouse model of severe factor VIII deficiency. British Journal Of Haematology 2012, 158: 140-143. PMID: 22469061, DOI: 10.1111/j.1365-2141.2012.09101.x.
- Chiu Y, Drolet B, Blei F, Carcao M, Fangusaro J, Kelly M, Krol A, Lofgren S, Mancini A, Metry D, Recht M, Silverman R, Tom W, Pope E. Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach–Merritt phenomenon. Pediatric Blood & Cancer 2012, 59: 934-938. PMID: 22648868, PMCID: PMC3528889, DOI: 10.1002/pbc.24103.
- Richard N, Haley K, Recht M. Thalassemia. 2012, 3029-3036. DOI: 10.1007/978-3-642-02202-9_326.
- Flood V, Recht M. Autoimmune Hemolytic Anemia. 2012, 2969-2974. DOI: 10.1007/978-3-642-02202-9_319.
- Bradeen H, Shehab S, Recht M. Iron Metabolism and Iron Deficiency Anemia. 2012, 2963-2968. DOI: 10.1007/978-3-642-02202-9_318.
- Wong T, Majumdar S, Adams E, Bergman S, Damiano M, Deutsche J, Recht M, Group H. Overweight and Obesity in Hemophilia A Systematic Review of the Literature. American Journal Of Preventive Medicine 2011, 41: s369-s375. PMID: 22099360, DOI: 10.1016/j.amepre.2011.09.008.
- Soucie J, De Staercke C, Chitlur M, Gruppo R, Hooper W, Kessler C, Kulkarni R, Manco-Johnson M, Monahan P, Oakley M, Powell J, Pyle M, Recht M, Riske B, Sabio H, Trimble S. Continued Transmission of Parvovirus B19 in Plasma-Derived Factor Concentrates After the Implementation of B19 Nucleic Acid Plasma Minipool Screening,. Blood 2011, 118: 3378. DOI: 10.1182/blood.v118.21.3378.3378.
- Chang L, Price S, Perkins K, Davis J, Aldridge P, Recht M, Kelleher J, Rao V. Mycophenolate Mofetil and Thrombopoietin Receptor Agonists in the Treatment of Refractory Thrombocytopenia in Patients with Autoimmune Lymphoproliferative Syndrome. Blood 2011, 118: 2218. DOI: 10.1182/blood.v118.21.2218.2218.
- Liel M, Klein R, Recht M, Greenberg D, Taylor J. Reduced Bone Mineral Density in Factor VIII Deficient Mice and the Role of Inflammatory Cytokines. Blood 2011, 118: 21. DOI: 10.1182/blood.v118.21.21.21.
- Grace R, Bennett C, Ritchey A, Jeng M, Thornburg C, Lambert M, Neier M, Recht M, Kumar M, Blanchette V, Klaassen R, Buchanan G, Kurth M, Nugent D, Thompson A, Stine K, Kalish L, Neufeld E. Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia. Pediatric Blood & Cancer 2011, 58: 221-225. PMID: 21674758, PMCID: PMC3863944, DOI: 10.1002/pbc.23130.
- RECHT M, POLLMANN H, TAGLIAFERRI A, MUSSO R, JANCO R, NEUMAN W. A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B. Haemophilia 2011, 17: 494-499. PMID: 21518148, DOI: 10.1111/j.1365-2516.2011.02436.x.
- SOUCIE J, WANG C, SIDDIQI A, KULKARNI R, RECHT M, KONKLE B, NETWORK T. The longitudinal effect of body adiposity on joint mobility in young males with Haemophilia A. Haemophilia 2011, 17: 196-203. PMID: 21332880, DOI: 10.1111/j.1365-2516.2010.02400.x.
- Wong T, Recht M. Current Options and New Developments in the Treatment of Haemophilia. Drugs 2011, 71: 305-320. PMID: 21319868, DOI: 10.2165/11585340-000000000-00000.
- Grace R, Bennett C, Ritchey A, Jeng M, Thornburg C, Lambert M, Neier M, Recht M, Kumar M, Blanchette V, Klaassen R, Buchanan G, Kurth M, Nugent D, Thompson A, Stine K, Kalish L, Neufeld E. Response to Steroids Predicts Response to Rituximab In Pediatric Chronic Immune Thrombocytopenia. Blood 2010, 116: 3681. DOI: 10.1182/blood.v116.21.3681.3681.
- Grace R, Neufeld E, Ritchey A, Kumar M, Jeng M, Blanchette V, Klaassen R, Buchanan G, Kurth M, Nugent D, Thompson A, Thornburg C, Lambert M, Neier M, Recht M, Stine K, Kalish L, Bennett C. The North American Chronic Immune Thrombocytopenia Registry (NACIR): Demographics and Treatment Responses. Blood 2010, 116: 2509. DOI: 10.1182/blood.v116.21.2509.2509.
- Neufeld E, Recht M, Sabio H, Cooper D, Wilke C, Pickard A, Gut R. PSY46 EFFECT OF ACUTE BLEEDING EPISODES ON QUALITY OF LIFE (QOL) IN PATIENTS WITH CONGENITAL HEMOPHILIA WITH INHIBITORS (CHWI) AND THEIR FAMILIES: OBSERVATIONS OF BLEED VS. NON-BLEED DAY QOL FROM THE DOSING OBSERVATIONAL STUDY IN HEMOPHILIA (DOSE) AND IMPLICATIONS FOR ASSESSMENT AND PREDICTION. Value In Health 2010, 13: a214. DOI: 10.1016/s1098-3015(10)73048-5.
- Recht M, Neufeld E, Sharma V, Cooper P, Wilke C, Pickard A, Gut R. PSY45 IMPACT OF ACUTE BLEEDING AND ADMINISTRATION OF BYPASSING AGENTS (BPA) ON DAILY ACTIVITIES OF PATIENTS WITH CONGENITAL HEMOPHILIA WITH INHIBITORS (CHWI) AND THEIR CAREGIVERS AND FAMILIES: OBSERVATIONS FROM THE DOSING OBSERVATIONAL STUDY IN HEMOPHILIA (DOSE). Value In Health 2010, 13: a214. DOI: 10.1016/s1098-3015(10)73047-3.
- Recht M. Thrombocytopenia and Anemia in Infants and Children. Emergency Medicine Clinics Of North America 2009, 27: 505-523. PMID: 19646651, DOI: 10.1016/j.emc.2009.04.009.
- RECHT M, NEMES L, MATYSIAK M, MANCO‐JOHNSON M, LUSHER J, SMITH M, MANNUCCI P, HAY C, ABSHIRE T, O’BRIEN A, HAYWARD B, UDATA C, ROTH D, ARKIN S. Clinical evaluation of moroctocog alfa (AF‐CC), a new generation of B‐domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full‐length recombinant factor VIII. Haemophilia 2009, 15: 869-880. PMID: 19473411, DOI: 10.1111/j.1365-2516.2009.02027.x.
- VALENTINO L, RECHT M, DIPAOLA J, SHAPIRO A, PIPE S, EWING N, URGO J, BULLOCK T, SIMMONS M, DEGUZMAN C. Experience with a third generation recombinant factor VIII concentrate (Advate®) for immune tolerance induction in patients with haemophilia A. Haemophilia 2009, 15: 718-726. PMID: 19298383, DOI: 10.1111/j.1365-2516.2008.01960.x.
- SPENCER M, WODRICH D, SCHULTZ W, WAGNER L, RECHT M. Inattention, hyperactivity‐impulsivity, academic skills and psychopathology in boys with and without haemophilia. Haemophilia 2009, 15: 701-706. PMID: 19298375, DOI: 10.1111/j.1365-2516.2009.01993.x.
- GERSTNER G, DAMIANO M, TOM A, WORMAN C, SCHULTZ W, RECHT M, STOPECK A. Prevalence and risk factors associated with decreased bone mineral density in patients with haemophilia. Haemophilia 2009, 15: 559-565. PMID: 19187193, DOI: 10.1111/j.1365-2516.2008.01963.x.
- Manco-Johnson M, Wagner L, Recht M, Knoll C, Geraghty S, Pounder E, Goldenberg N. Successful Control of Refractory Inhibitors in Children with Hemophilia a Using Multiple Agent Immune Modulation. Blood 2008, 112: 2283. DOI: 10.1182/blood.v112.11.2283.2283.
- Gerstner G, Damiano M, Tom A, Worman C, Schultz W, Recht M, Stopeck A. Decreased Bone Mineral Density among Patients with Hemophilia. Blood 2007, 110: 1153. DOI: 10.1182/blood.v110.11.1153.1153.
- Recht M, Nemes L, O'Brien A, Udata C, Roth D, Arkin S. ReFacto AF Is Effective and Safe in Previously Treated Patients with Severe Hemophilia A: Final Results of a Pivotal Phase III Study. Blood 2007, 110: 1151. DOI: 10.1182/blood.v110.11.1151.1151.
- LAMBERT T, RECHT M, VALENTINO L, POWELL J, UDATA C, SULLIVAN S, ROTH D. Reformulated BeneFix®: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B. Haemophilia 2007, 13: 233-243. PMID: 17498071, DOI: 10.1111/j.1365-2516.2007.01458.x.
- Hay C, Recht M, Carcao M, Reipert B. Current and Future Approaches to Inhibitor Management and Aversion. Seminars In Thrombosis And Hemostasis 2006, 32: 015-021. PMID: 16804831, DOI: 10.1055/s-2006-946910.
- Powell J, Lambert T, Navarro F, Recht M, Sullivan S, Udata C, Lilly L, Roth D. A New Formulation of Recombinant Human Factor IX Is Bioequivalent to BeneFIX: A Double-Blind, Randomized, Crossover Pharmacokinetic and Open-Label Safety and Efficacy Study. Blood 2005, 106: 4076. DOI: 10.1182/blood.v106.11.4076.4076.
- Wodrich D, Recht M, Gradowski M, Wagner L. Is attention deficit hyperactivity disorder over‐represented among HIV‐seronegative boys with haemophilia? Preliminary results from our centre. Haemophilia 2003, 9: 593-597. PMID: 14511300, DOI: 10.1046/j.1365-2516.2003.00790.x.
- Rincón M, Enslen H, Raingeaud J, Recht M, Zapton T, Su M, Penix L, Davis R, Flavell R. Interferon‐γ expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway. The EMBO Journal 1998, 17: 2817-2829. PMID: 9582275, PMCID: PMC1170622, DOI: 10.1093/emboj/17.10.2817.
- Recht M, Xu S, Penix L. p38 MAP kinase is critical for the transcriptional regulation of the human interferon-γ gene. ♦ 58. Pediatric Research 1997, 41: 12-12. DOI: 10.1203/00006450-199704001-00079.
Departments and Programs
Locations
1
YNHCH Pediatric Specialty Center at Trumbull
Trumbull Pediatric Specialty Center
5520 Park Avenue, Ste 600
Trumbull, CT 06611
1 of 3
- YNHCH Pediatric Specialty Center at TrumbullTrumbull Pediatric Specialty Center5520 Park Avenue, Ste 600Trumbull, CT 06611
- Smilow Cancer HospitalSmilow Cancer Hospital at Yale New Haven35 Park Street, Wing North Pavilion Fl 7New Haven, CT 06511
- YNHCH Pediatric Specialty Center at Old SaybrookOld Saybrook Medical Center633 Middlesex Turnpike, Ste 110Old Saybrook, CT 06475
Biography
Michael Recht, MD, PhD, is a pediatric hematologist who focuses on treating children, adolescents, and young adults with bleeding and clotting disorders.
Dr. Recht is a professor of clinical pediatrics at Yale School of Medicine. He has been actively involved in more than 110 clinical trials, including research on gene therapy for hemophilia. Dr. Recht also serves as the chief medical and scientific officer for the National Bleeding Disorders Foundation. In this role, he helps shape the scientific direction and research strategy of the organization, working to advance the understanding and treatment of bleeding disorders. Dr. Recht received his medical and doctoral degrees from the University of Wisconsin-Madison. He completed his residency in pediatrics and fellowship in pediatric hematology-oncology at Yale New Haven Hospital.
Titles
- Professor of Clinical Pediatrics (Hematology/Oncology)
- Chief Medical and Scientific Officer, National Hemophilia Foundation, National Hemophilia Foundation
Education & Training
- MBAOregon Health & Science University/Portland State University (2016)
- FellowYale University School of Medicine (1998)
- ResidentYale New Haven Hospital (1995)
- MDUniversity of Wisconsin-Madison (1992)
- PhDUniversity of Wisconsin-Madison (1990)
Additional Information
Publications
- von Drygalski A, Gomez E, Giermasz A, Castaman G, Key N, Lattimore S, Leebeek F, Miesbach W, Recht M, Monahan P, Le Quellec S, Pipe S. Completion of Phase 2b trial of etranacogene dezaparvovec gene therapy in patients with hemophilia B over 5 years. Blood Advances 2025 PMID: 40188458, DOI: 10.1182/bloodadvances.2024015291.
- Konkle B, Peyvandi F, Foster G, Hermans C, La Mura V, Leavitt A, Lillicrap D, Mahlangu J, Ozelo M, Pipe S, Recht M, Srivastava A, Young G, Miesbach W. Corticosteroid use to mitigate transaminitis-associated decline in FVIII levels following valoctocogene roxaparvovec gene therapy: clinical practice guidance. Journal Of Thrombosis And Haemostasis 2025 PMID: 40090623, DOI: 10.1016/j.jtha.2025.02.042.
- Chrisentery‐Singleton T, Gattone P, Gerber C, Mills K, Miles M, Rotellini D, Santaella M, Valentino L, Watson C, Recht M. American Thrombosis and Hemostasis Network: National Bleeding Disorders Foundation Data Commons: Better Together. Haemophilia 2025 PMID: 39982786, DOI: 10.1111/hae.70011.
- Valentino L, Santaella M, Carlson S, Recht M. Contemporary approaches to treat people with hemophilia: what’s new and what’s not? Research And Practice In Thrombosis And Haemostasis 2025, 9: 102696. PMID: 40084158, PMCID: PMC11905833, DOI: 10.1016/j.rpth.2025.102696.
- Dunn A, Dargaud Y, Abajas Y, Carcao M, Castaman G, Giermasz A, Hermans C, Jiménez‐Yuste V, Lewandowska M, Mahlangu J, Meeks S, Miesbach W, Recht M, Salinas V, Chrisentery‐Singleton T, Bonzo D, Mitchell I, Wilkinson T, Young G. Bleed treatment with eptacog beta (rFVIIa) results in a low incidence of rebleeding in adult and adolescent patients with haemophilia A or B with inhibitors. Haemophilia 2024, 31: 78-86. PMID: 39676340, PMCID: PMC11780187, DOI: 10.1111/hae.15109.
- Skinner M, Albisetti M, Ardila J, Astermark J, Blatny J, Carcao M, Chowdary P, Connell N, Crato M, Dargaud Y, d'Oiron R, Dunn A, Escobar M, Escuriola‐Ettingshausen C, Gouider E, Harroche A, Hermans C, Jimenez‐Yuste V, Kaczmarek R, Kenet G, Khoo L, Klamroth R, Langer F, Lillicrap D, Mahlangu J, Male C, Matsushita T, Meunier S, Miesbach W, Nolan B, Oldenburg J, O'Mahony B, Ozelo M, Pierce G, Ramos G, Recht M, Romero‐Lux O, Rotellini D, Santoro R, Singleton T, Srivastava A, Susen S, Talks K, Tran H, Valentino L, Windyga J, Yang R, Mancuso M, also on behalf of AICE A. Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and Von Willebrand Disease. Haemophilia 2024 PMID: 39648854, DOI: 10.1111/hae.15136.
- Albisetti M, Ardila J, Astermark J, Blatny J, Carcao M, Chowdary P, Connell N, Crato M, Dargaud Y, d'Oiron R, Dunn A, Escobar M, Ettingshausen C, Fischer K, Gouider E, Harroche A, Hermans C, Jimenez‐Yuste V, Kaczmarek R, Kenet G, Khoo L, Klamroth R, Langer F, Lillicrap D, Mahlangu J, Male C, Mancuso M, Matsushita T, Meunier S, Miesbach W, Nolan B, Oldenburg J, O'Mahony B, Ozelo M, Pierce G, Ramos G, Recht M, Romero‐Lux O, Rotellini D, Santoro R, Singleton T, Skinner M, Srivastava A, Susen S, Talks K, Tran H, Valentino L, Windyga J, Yang R, also on behalf of AICE A. International Society on Thrombosis and Haemostasis Clinical Practice Guideline for Treatment of Congenital Haemophilia—A Critical Appraisal. Haemophilia 2024 PMID: 39642092, DOI: 10.1111/hae.15135.
- Chandler M, Moulton T, Charafi L, Charlet J, Recht M. Effectiveness of Damoctocog Alfa Pegol to Treat Patients With Hemophilia A Enrolled in the ATHNdataset. European Journal Of Haematology 2024, 114: 448-457. PMID: 39558414, PMCID: PMC11798759, DOI: 10.1111/ejh.14337.
- Corrales-Medina F, Afari-Dwamena N, Blair A, Carpenter S, Chrisentery-Singleton T, Daoud N, Janbain M, Raffini L, Schwartz J, Zia A, Recht M. ATHN Transcends Hemophilia Natural History Arm: Baseline Characteristics, Adverse Events, and Self-Reported Health Status of Individuals with Hemophilia A and B. Blood 2024, 144: 1204. DOI: 10.1182/blood-2024-198548.
- Buckner T, Kessler C, Castaman G, Hermans C, Jimenez-Yuste V, Mahlangu J, Miesbach W, Oldenburg J, Recht M, Valentino L, Wheeler A, Pipe S. Pain Reduction Following Treatment of Bleeding Episodes with Eptacog Beta in Adults and Adolescents with Hemophilia A or B Complicated By Inhibitors. Blood 2024, 144: 3972-3972. DOI: 10.1182/blood-2024-194935.
- Youkhana K, Batsuli G, Acharya S, Khan O, Tran D, Dvorak A, Recht M, Young G, Sidonio R, Abajas Y. Real‐world effectiveness of eptacog beta in patients with haemophilia and inhibitors: A multi‐institutional case series. Haemophilia 2024, 30: 1321-1331. PMID: 39297369, PMCID: PMC11659498, DOI: 10.1111/hae.15094.
- DeSancho M, Suvar E, Roberts J, Tarantino M, Schwartz J, Callis J, Recht M. Hereditary antithrombin deficiency pilot project registry from the American Thrombosis and Hemostasis Network. Journal Of Thrombosis And Haemostasis 2024, 22: 3183-3190. PMID: 39151704, DOI: 10.1016/j.jtha.2024.07.026.
- Pierce G, O'Mahony B, Kaczmarek R, Skinner M, Makris M, Peyvandi F, Srivastava A, Hermans C, World Federation of Hemophilia Coagulation Products Supply S, Crato M, Dunn A, Gouider E, Mahlangu J, Page D, Pipe S, Recht M, Sannie T, Schaefer N, Schlenkrich U, Garrido C. Risk of harm to people with haemophilia from the 2023 WHO Essential Medicines List. The Lancet Haematology 2024, 11: e638-e640. PMID: 39116903, DOI: 10.1016/s2352-3026(24)00223-0.
- Nolan B, Recht M, Rendo P, Falk A, Foster M, Casiano S, Rauch A, Shapiro A. Prophylaxis with recombinant factor IX Fc fusion protein reduces the risk of bleeding and delays time to first spontaneous bleed event in previously untreated patients with haemophilia B: A post hoc analysis of the PUPs B‐LONG study. European Journal Of Haematology 2024, 113: 485-492. PMID: 38922990, DOI: 10.1111/ejh.14252.
- Hu J, Chandler M, Manuel C, Caicedo J, Denne M, Ewenstein B, Mokdad A, Xing S, Recht M. Risk of Intracranial Hemorrhage in Persons with Hemophilia A in the United States: Real-World Retrospective Cohort Study Using the ATHNdataset. Journal Of Blood Medicine 2024, 15: 191-205. PMID: 38699197, PMCID: PMC11063465, DOI: 10.2147/jbm.s443380.
- Itzler R, Buckner T, Leebeek F, Miller J, Recht M, Drelich D, Monahan P, Pipe S. Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE‐B trial 2 years after gene therapy. Haemophilia 2024, 30: 709-719. PMID: 38462823, DOI: 10.1111/hae.14977.
- Ragni M, Callis J, Daoud N, Hu B, Manuel M, Santos J, Schwartz J, Friedman K, Kouides P, Kuriakose P, Leavitt A, Lim M, Machin N, Recht M, Chrisentery‐Singleton T. Observational cohort study of long‐term outcomes of liver transplantation in haemophilia. Haemophilia 2023, 30: 87-97. PMID: 38111071, DOI: 10.1111/hae.14910.
- Chandler M, Charlet J, Moulton T, Recht M. Real-World Data on Hemophilia a Patients Transitioning from Bay 81-8973 to Bay 94-9027 and from Bay 14-2222 to Bay 81-8973 and then to Bay 94-9027 in the Athndataset. Blood 2023, 142: 5479. DOI: 10.1182/blood-2023-188995.
- Reiss U, Davidoff A, Tuddenham E, Chowdary P, McIntosh J, Riddell A, Pie A, Batty P, Calvert J, Mangles S, Mahlangu J, Haley K, Recht M, Shen Y, Halka K, Zhou J, Kang G, Okhomina V, Morton C, Nathwani A. Stable Therapeutic Transgenic FIX Levels for More Than 10 Years in Subjects with Severe Hemophilia B Who Received scAAV2/8-LP1-Hfixco Adeno-Associated Virus Gene Therapy. Blood 2023, 142: 1056. DOI: 10.1182/blood-2023-186891.
- Santaella M, Raimundo K, Schuldt R, Recht M. Comparison of Projected Hemophilia a Populations Residing in Hospital Referral Regions with and without Hemophilia Treatment Centers in the US. Blood 2023, 142: 3696. DOI: 10.1182/blood-2023-181009.
- Buckner T, Daoud N, Lee L, Lim E, Schwartz J, Raimundo K, Recht M. Quality of Life in Emicizumab-Treated People with Hemophilia A in the ATHN 7 Hemophilia Natural History Study - an Assessment of Baseline PROMIS®-29 Scores. Blood 2023, 142: 3998. DOI: 10.1182/blood-2023-174092.
- Santaella M, Carlson L, DiMichele D, Norris K, Valadez S, Valentino L, Vazquez E, Witkop M, Recht M. Walking the Walk: Inclusion of Lived Experience Experts in the Design of the National Hemophilia Foundation's National Research Blueprint for Those Living with Inherited Bleeding Disorders. Blood 2023, 142: 7216. DOI: 10.1182/blood-2023-186109.
- Chrisentery-Singleton T, O'Neill C, Rea C, Amin J, Recht M. Athn Transcends Natural History Cohort Study of Bleeding Symptoms and Treatment Outcomes in Patients with Glanzmann Thrombasthenia. Blood 2023, 142: 5457. DOI: 10.1182/blood-2023-190090.
- DeSancho M, Suvar E, Roberts J, Tarantino M, Santos J, Manuel M, Recht M. PB0987 Hereditary Antithrombin Deficiency Pilot Project Registry from the American Thrombosis and Hemostasis Network (ATHN). Research And Practice In Thrombosis And Haemostasis 2023, 7: 101802. DOI: 10.1016/j.rpth.2023.101802.
- Tootoonchian E, Stonebraker J, Iorio A, El-Ekiaby M, Gouider E, Makris M, O'Hara J, Recht M, Pierce G, Coffin D. PB0837 Analysis of the Change in Diagnosis of von Willebrand Disease by Region and Economic Status. Research And Practice In Thrombosis And Haemostasis 2023, 7: 101562. DOI: 10.1016/j.rpth.2023.101562.
- Singleton T, Acharya S, Ahuja S, Amos L, Bonzo D, Eason A, Escobar M, Knoll C, Kuriakose P, Lagrue E, Recht M, Sullivan S, Quon D, Reding M. PB0323 Preliminary Analysis of ATHN 16: Real-World Safety of Eptacog Beta. Research And Practice In Thrombosis And Haemostasis 2023, 7: 101463. DOI: 10.1016/j.rpth.2023.101463.
- Malec L, Bialas R, O'Neill C, Thibaudeau K, Warner E, Weigel E, Recht M. PB0229 Designing the Ryplazim® (Plasminogen, Human-tvmh) Arm of Athn Transends: Safety and Effectiveness in People with Plasminogen Deficiency. Research And Practice In Thrombosis And Haemostasis 2023, 7: 101264. DOI: 10.1016/j.rpth.2023.101264.
- Youttananukorn T, Konkle B, Coffin D, Naccache M, Clark C, George L, Iorio A, Miesbach W, Noone D, Peyvandi F, Pipe S, Recht M, Skinner M, Valentino L, Mahlangu J, Pierce G. PB0191 myGTR: A Patient Engagement Tool from the World Federation of Hemophilia Gene Therapy Registry. Research And Practice In Thrombosis And Haemostasis 2023, 7: 101212. DOI: 10.1016/j.rpth.2023.101212.
- Buckner T, Daoud N, Lee L, Morton P, O'Neill C, Wang M, Recht M. PB0625 Emicizumab Prophylaxis in People with Hemophilia A Aged >50 Years withComorbidities:ExperienceFromtheATHN7Hemophilia Natural History Study. Research And Practice In Thrombosis And Haemostasis 2023, 7: 101210. DOI: 10.1016/j.rpth.2023.101210.
- Malec L, Carpenter S, O'Neill C, Thornburg C, Recht M. PB0629 Designing the Efanesoctocog Alfa Module of ATHN Transcends: Safety, Tolerability, and Effectiveness in Previously Untreated Patients with Hemophilia A. Research And Practice In Thrombosis And Haemostasis 2023, 7: 101199. DOI: 10.1016/j.rpth.2023.101199.
- Recht M, Charlet J, Moulton T, Chandler M. PB0672 Real-World Data on Hemophilia A Patients Switching to Either BAY 94-9027 or BAY 81-8973 from Emicizumab Using the ATHNdataset. Research And Practice In Thrombosis And Haemostasis 2023, 7: 101169. DOI: 10.1016/j.rpth.2023.101169.
- Ragni M, Hu B, Callis J, Manuel M, Santos J, Friedman K, Kouides P, Kuriakose P, Leavitt A, Lim M, Machin N, Recht M. PB1241 ATHN 11: Observational Study of Long-Term Outcomes of Liver Transplantation. Research And Practice In Thrombosis And Haemostasis 2023, 7: 101135. DOI: 10.1016/j.rpth.2023.101135.
- Recht M, Charlet J, Moulton T, Chandler M. PB1278 Real-World Data on Hemophilia A Patients with Inhibitors Switching to Either BAY 94-9027 or BAY 81-8973 in the ATHNdataset. Research And Practice In Thrombosis And Haemostasis 2023, 7: 101124. DOI: 10.1016/j.rpth.2023.101124.
- Recht M, Charafi L, Moulton T, Chandler M. PB1291 Joint Range of Motion Findings Among Female Patients with Hemophilia A from the ATHNdataset. Research And Practice In Thrombosis And Haemostasis 2023, 7: 101103. DOI: 10.1016/j.rpth.2023.101103.
- Nugent D, Williams S, Ashburner C, Crook N, Momoh H, Recht M, Chandler M, Shapiro A. OC 75.1 First US Rare Bleeding Disorder Genotype-Phenotype Registry (ATHN 10) Discovers Many Individuals with Both Novel and Multiple Variants using a Customized 30-Gene Next-Generation Sequencing Panel. Research And Practice In Thrombosis And Haemostasis 2023, 7: 100478. DOI: 10.1016/j.rpth.2023.100478.
- Miesbach W, Recht M, Key N, Guillen-Gonzalez R, Sivamurthy K, Monahan P, Pipe S. OC 52.1 Assessing the Safety Profile of AMT-060 and Etranacogene Dezaparvovec Gene Therapies Across Clinical Trials in People with Severe/Moderately Severe Hemophilia B. Research And Practice In Thrombosis And Haemostasis 2023, 7: 100456. DOI: 10.1016/j.rpth.2023.100456.
- Pipe S, Leebeek F, Recht M, Key N, Lattimore S, Castaman G, Coppens M, Li Y, Monahan P, Miesbach W. OC 52.5 Phase 3 HOPE-B Trial of Etranacogene Dezaparvovec in Severe/Moderately Severe Hemophilia B: A Post Hoc Responder Analysis of Participants Who Received Full Dose and Responded to Treatment. Research And Practice In Thrombosis And Haemostasis 2023, 7: 100448. DOI: 10.1016/j.rpth.2023.100448.
- Konkle B, Coffin D, Naccache M, Youttananukorn T, Clark C, George L, Iorio A, Miesbach W, Noone D, Peyvandi F, Pipe S, Recht M, Skinner M, Valentino L, Mahlangu J, Pierce G. OC 20.5 The WFH Gene Therapy Registry: A Collaborative Approach Towards a Global Resource for the Long-Term Follow-up of People with Hemophilia Treated with Gene Therapy. Research And Practice In Thrombosis And Haemostasis 2023, 7: 100445. DOI: 10.1016/j.rpth.2023.100445.
- Chelle P, Hajducek D, Daoud N, Iserman E, Gerber C, Germini F, Iorio A, Edginton A, Recht M. OC 24.2 Estimated Factor VIII Activity Levels at the Time of Bleeding Events in Individuals with Hemophilia a Without Inhibitors. Research And Practice In Thrombosis And Haemostasis 2023, 7: 100436. DOI: 10.1016/j.rpth.2023.100436.
- von Drygalski A, Gomez E, Giermasz A, Castaman G, Key N, Lattimore S, Leebeek F, Miesbach W, Recht M, Gut R, Dolmetsch R, Monahan P, Le Quellec S, Pipe S. Stable and durable factor IX levels in hemophilia B patients over 3 years post etranacogene dezaparvovec gene therapy. Blood Advances 2023, 7: 5671-5679. PMID: 36490302, PMCID: PMC10539871, DOI: 10.1182/bloodadvances.2022008886.
- Nugent D, Acharya S, Baumann K, Bedrosian C, Bialas R, Brown K, Corzo D, Haidar A, Hayward C, Marks P, Menegatti M, Miller M, Nammacher K, Palla R, Peltier S, Pruthi R, Recht M, Sørensen B, Tarantino M, Wolberg A, Shapiro A. Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for ultra-rare inherited bleeding disorders. Expert Review Of Hematology 2023, 16: 55-70. PMID: 36920862, PMCID: PMC10020868, DOI: 10.1080/17474086.2023.2175661.
- Valentino L, Witkop M, Santaella M, DiMichele D, Recht M. The National Hemophilia Foundation’s State of the Science Research Summit: the foundation of a national research blueprint for inherited bleeding disorders. Expert Review Of Hematology 2023, 16: 1-5. PMID: 36920858, DOI: 10.1080/17474086.2023.2178412.
- Valentino L, Witkop M, Santaella M, DiMichele D, Recht M. The National Hemophilia Foundation State of the Science Research Summit initiative: executive summary. Expert Review Of Hematology 2023, 16: 129-134. PMID: 36920857, DOI: 10.1080/17474086.2023.2181782.
- Messenger H, Kulkarni R, Recht M, He C. A Retrospective Analysis of the American Thrombosis and Hemostasis Network Dataset Describing Outcomes of Dental Extractions in Persons with Hemophilia. Journal Of Clinical Medicine 2023, 12: 1839. PMID: 36902626, PMCID: PMC10002874, DOI: 10.3390/jcm12051839.
- Parker K, Durben N, Oleson D, Yu Y, Lim J, Recht M, Lindemulder S. Hopping as an Indicator of Chemotoxicity: Gait Analysis in Patients With Leukemia and Lymphoma. Journal Of Pediatric Hematology/Oncology 2023, 45: e582-e589. PMID: 36898017, DOI: 10.1097/mph.0000000000002645.
- Pipe S, Leebeek F, Recht M, Key N, Castaman G, Miesbach W, Lattimore S, Peerlinck K, Van der Valk P, Coppens M, Kampmann P, Meijer K, O’Connell N, Pasi K, Hart D, Kazmi R, Astermark J, Hermans C, Klamroth R, Lemons R, Visweshwar N, von Drygalski A, Young G, Crary S, Escobar M, Gomez E, Kruse-Jarres R, Quon D, Symington E, Wang M, Wheeler A, Gut R, Liu Y, Dolmetsch R, Cooper D, Li Y, Goldstein B, Monahan P. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B. New England Journal Of Medicine 2023, 388: 706-718. PMID: 36812434, DOI: 10.1056/nejmoa2211644.
- Pipe W, Leebeek W, Recht M, Key S, Lattimore S, Castaman G, Coppens M, Cooper D, Gut R, Slawka S, Verweij S, Dolmetsch R, Li Y, Monahan P, Miesbach W. Adults with severe or moderately severe haemophilia B receiving etranacogene dezaparvovec in the HOPE-B phase 3 trial experience a stable increase in mean Factor IX activity levels and durable haemostatic protection after 24 months’ follow-up. Hämostaseologie 2023, 43: s44-s45. DOI: 10.1055/s-0042-1760523.
- Miesbach W, Recht M, Key N, Sivamurthy K, Monahan E, Pipe W. Durability of Factor IX activity and bleeding rate in people with severe or moderately severe haemophilia B after long-term follow-up in the phase 1/2 Study of AMT-060, and phase 2b and phase 3 studies of etranacogene dezaparvovec (AMT-061). Hämostaseologie 2023, 43: s46-s47. DOI: 10.1055/s-0042-1760526.
- Pipe W, Leebeek W, Recht M, Key S, Lattimore S, Castaman G, Cooper D, Verweij S, Dolmetsch R, Tarrant J, Li Y, Monahan E, Miesbach W. Durability of bleeding protection and Factor IX activity in individuals with and without adeno-associated virus serotype 5 neutralising antibodies (Titres <1:700) in the phase 3 HOPE-B trial of etranacogene dezaparvovec gene therapy for haemophilia B. Hämostaseologie 2023, 43: s45-s45. DOI: 10.1055/s-0042-1760524.
- Corrales-Medina F, Raffini L, Recht M, Santos J, Thornburg C, Davila J, Investigators A. Direct oral anticoagulants in pediatric venous thromboembolism: Experience in specialized pediatric hemostasis centers in the United States. Research And Practice In Thrombosis And Haemostasis 2022, 7: 100001. PMID: 36970740, PMCID: PMC10031368, DOI: 10.1016/j.rpth.2022.100001.
- Pipe S, Leebeek F, Recht M, Key N, Lattimore S, Castaman G, Coppens M, Cooper D, Gut R, Slawka S, Verweij S, Dolmetsch R, Li Y, Monahan P, Miesbach W. Adults with Severe or Moderately Severe Hemophilia B Receiving Etranacogene Dezaparvovec in the HOPE-B Phase 3 Clinical Trial Continue to Experience a Stable Increase in Mean Factor IX Activity Levels and Durable Hemostatic Protection after 24 Months’ Follow-up. Blood 2022, 140: 4910-4912. DOI: 10.1182/blood-2022-166135.
- Hu B, Chandler M, Manuel M, Caicedo J, Denne M, Ewenstein B, Mokdad A, Xing S, Recht M. Risk of Intracranial Hemorrhage in US Patients with Hemophilia a: Real-World Retrospective Cohort Study Using the Athndataset. Blood 2022, 140: 2722-2723. DOI: 10.1182/blood-2022-163861.
- Chrisentery-Singleton T, Amos L, Bonzo D, Escobar M, Giermasz A, Lagrue E, Knoll C, Nasr S, Recht M, Sullivan S, Quon D, Reding M. A Preliminary Analysis of Athn 16: Safety of Coagulation Factor VIIa (recombinant)-Jncw for the Treatment of Bleeding Events in Patients with Congenital Hemophilia a or B with Inhibitors. Blood 2022, 140: 11360-11361. DOI: 10.1182/blood-2022-163372.
- Weyand A, Chandler M, Fedor C, Recht M, Sidonio R. Quality of Life in Patients with Clinically Severe Von Willebrand Disease: Interim Analysis of Athn 9: A Natural History Study for People with Severe Von Willebrand Disease (VWD). Blood 2022, 140: 5600-5602. DOI: 10.1182/blood-2022-163302.
- Carpenter S, Chandler M, Guerrera M, Malec L, Manuel M, Recht M, Reiss U, Sidonio R, Tarango C, Van den Berg M, Wang M, Thornburg C. U.S. Cohort Study of Previously Untreated Patients with Congenital Hemophilia (ATHN 8: PUPs Study): Inhibitor Development and Treatment Characteristics. Blood 2022, 140: 63-64. DOI: 10.1182/blood-2022-162660.
- Swaminathan N, Hu B, Currie A, Kulkarni R, Pipe S, Recht M, Kouides P, Sharathkumar A. Characterization of Bleeding and Laboratory Phenotype of Carriers of Hemophilia and Trends of Utilization of Factor Concentrates and Hemostatic Therapies: Analysis of the National Athndataset. Blood 2022, 140: 59-60. DOI: 10.1182/blood-2022-158861.
- Decker-Palmer M, Mathias S, Colwell H, Crosby R, Gentile B, Chupka J, Sidonio R, Recht M, Shapiro A, Zazzali J. Performance of the Comprehensive Assessment Tool for Challenges in Hemophilia (CATCH) 2.0. Blood 2022, 140: 11328-11329. DOI: 10.1182/blood-2022-157932.
- Recht M, Daoud N, Lee L, Morton P, Raffini L. Emicizumab and Females with Hemophilia A: Case Series from ATHN 7. Blood 2022, 140: 2745-2746. DOI: 10.1182/blood-2022-157754.
- Dunn A, Dargaud Y, Abajas Y, Carcao M, Castaman G, Giermasz A, Hermans C, Lewandowska M, Mahlangu J, Meeks S, Miesbach W, Recht M, Salinas V, Chrisentery-Singleton T, Wang H, Mitchell I, Young G. Eptacog Beta (rFVIIa) Has a Low Incidence of Spontaneous Rebleeding through 24 and 48 Hours in Adult and Adolescent Patients with Hemophilia A or B with Inhibitors. Blood 2022, 140: 8485-8488. DOI: 10.1182/blood-2022-157343.
- Witkop M, Santaella M, Recht M, Norris K, Spitale B, Vasquez E, DiMichele D, Mills K. National Hemophilia Foundation Champions a National Research Blueprint Defining a Community-Coordinated Research Ecosystem to Accelerate Progress in Inherited Bleeding Disorders. Blood 2022, 140: 5021-5022. DOI: 10.1182/blood-2022-170842.
- DeSancho M, Suvar E, Roberts J, Tarantino M, Santos J, Recht M. Hereditary Antithrombin Deficiency Pilot Project Registry from the American Thrombosis and Hemostasis Network (ATHN). Blood 2022, 140: 5670-5672. DOI: 10.1182/blood-2022-168179.
- Miesbach W, Recht M, Key N, Sivamurthy K, Monahan P, Pipe S. Durability of Factor IX Activity and Bleeding Rate in People with Severe or Moderately Severe Hemophilia B after 5 Years of Follow-up in the Phase 1/2 Study of AMT-060, and after 3 Years of Follow-up in the Phase 2b and 2 Years of Follow-up in the Phase 3 Studies of Etranacogene Dezaparvovec (AMT-061). Blood 2022, 140: 4913-4914. DOI: 10.1182/blood-2022-166810.
- Pipe S, Leebeek F, Recht M, Key N, Lattimore S, Castaman G, Cooper D, Verweij S, Dolmetsch R, Tarrant J, Li Y, Monahan P, Miesbach W. Durability of Bleeding Protection and Factor IX Activity Levels Are Demonstrated in Individuals with and without Adeno-Associated Virus Serotype 5 Neutralizing Antibodies (Titers <1:700) with Comparable Safety in the Phase 3 HOPE-B Clinical Trial of Etranacogene Dezaparvovec Gene Therapy for Hemophilia B. Blood 2022, 140: 4904-4906. DOI: 10.1182/blood-2022-166745.
- Chandler M, Charlet J, Moulton T, Recht M. Real-World Use of Octocog Alfa and Damoctocog Alfa Pegol in Women with Hemophilia a from the ATHNdataset. Blood 2022, 140: 2751-2752. DOI: 10.1182/blood-2022-166669.
- Johnsen J, Fletcher S, Dove A, McCracken H, Martin B, Kircher M, Josephson N, Shendure J, Ruuska S, Valentino L, Pierce G, Watson C, Cheng D, Recht M, Konkle B. Results of genetic analysis of 11 341 participants enrolled in the My Life, Our Future hemophilia genotyping initiative in the United States. Journal Of Thrombosis And Haemostasis 2022, 20: 2022-2034. PMID: 35770352, DOI: 10.1111/jth.15805.
- Roberts J, Richardson S, Miles M, Stanley J, Chapman C, Denne M, Caicedo J, Rockwood K, Recht M. The GOAL‐Hēm journey: Shared decision making and patient‐centred outcomes. Haemophilia 2022, 28: 784-795. PMID: 35728103, PMCID: PMC9546188, DOI: 10.1111/hae.14608.
- Valentino L, Witkop M, Santaella M, DiMichele D, Recht M. Building the blueprint: Formulating a community‐generated national plan for future research in inherited bleeding disorders. Haemophilia 2022, 28: 760-768. PMID: 35700441, PMCID: PMC9546016, DOI: 10.1111/hae.14588.
- Rauch A, Valentino L, Mills K, Witkop M, Santaella M, DiMichele D, Recht M, Susen S. Big picture initiatives in bleeding disorders. Haemophilia 2022, 28: 53-60. PMID: 35521733, DOI: 10.1111/hae.14532.
- Pipe S, Hermans C, Chitlur M, Carcao M, Castaman G, Davis J, Ducore J, Dunn A, Escobar M, Journeycake J, Khan O, Mahlangu J, Meeks S, Mitha I, Négrier C, Nowak‐Göttl U, Recht M, Chrisentery‐Singleton T, Stasyshyn O, Vilchevska K, Martinez L, Wang M, Windyga J, Young G, Alexander W, Bonzo D, Macie C, Mitchell I, Sauty E, Wilkinson T, Shapiro A. Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors. Haemophilia 2022, 28: 548-556. PMID: 35475308, PMCID: PMC9542908, DOI: 10.1111/hae.14563.
- Recht M, He C, Chen E, Cheng D, Solari P, Hinds D. Resource utilization and treatment costs of patients with severe hemophilia A: Real‐world data from the ATHNdataset. EJHaem 2022, 3: 341-352. PMID: 35846041, PMCID: PMC9176109, DOI: 10.1002/jha2.412.
- Burke T, Shaikh A, Ali T, Li N, Curtis R, Diego D, Recht M, Sannie T, Skinner M, O’Hara J. Association of factor expression levels with health-related quality of life and direct medical costs for people with haemophilia B. Journal Of Medical Economics 2022, 25: 386-392. PMID: 35253589, DOI: 10.1080/13696998.2022.2049552.
- Roberts J, Recht M, Gonzales S, Stanley J, Denne M, Caicedo J, Rockwood K. Incorporating the patient voice and patient engagement in GOAL‐Hēm: Advancing patient‐centric hemophilia care. Research And Practice In Thrombosis And Haemostasis 2022, 6: e12655. PMID: 35155975, PMCID: PMC8822263, DOI: 10.1002/rth2.12655.
- Burke T, Shaikh A, Ali T, Lickorish D, Li N, Curtis R, García-Diego D, Recht M, Sannié T, Skinner M, O'Hara J. POSC415 Economic and Health-Related Quality of Life Data across Baseline Fix Expression Levels in People with Haemophilia B: An Analysis Using the Factor Expression Study. Value In Health 2022, 25: s270. DOI: 10.1016/j.jval.2021.11.1316.
- Buckner T, Daoud N, Miles M, O'Neill C, Watson C, Recht M. Designing ATHN 7: Safety, effectiveness and practice of treatment of people with haemophilia in the United States through a natural history cohort study. The Journal Of Haemophilia Practice 2022, 9: 147-155. DOI: 10.2478/jhp-2022-0020.
- George L, Monahan P, Eyster M, Sullivan S, Ragni M, Croteau S, Rasko J, Recht M, Samelson-Jones B, MacDougall A, Jaworski K, Noble R, Curran M, Kuranda K, Mingozzi F, Chang T, Reape K, Anguela X, High K. Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A. New England Journal Of Medicine 2021, 385: 1961-1973. PMID: 34788507, PMCID: PMC8672712, DOI: 10.1056/nejmoa2104205.
- He C, Hinds D, Pezalla E, Cheng D, Chen E, Sammon J, Solari P, Recht M. Health insurance coverage and switching among people with hemophilia A in the United States. Journal Of Managed Care & Specialty Pharmacy 2021, 28: 232-243. PMID: 34780299, DOI: 10.18553/jmcp.2021.21311.
- Chandler M, Recht M, He C, Moulton T, Charafi L. Real-World Effectiveness of Damoctocog Alfa Pegol in the Subgroup of Adolescent Hemophilia A Patients Aged 12-18 Years in the ATHNdataset. Blood 2021, 138: 4241. DOI: 10.1182/blood-2021-152345.
- Witkop M, Recht M, DiMichele D, Mills K, Valentino L, Santaella M. National Hemophilia Foundation Convenes Diverse Community Voices to Define an Actionable National Research Blueprint for Inherited Bleeding Disorders. Blood 2021, 138: 4952. DOI: 10.1182/blood-2021-149518.
- Nolan B, Recht M, Rendo P, Falk A, Foster M, Casiano S, Rauch A, Shapiro A. Prophylaxis with rFIXFc Reduces the Frequency and Delays Time to First Spontaneous Bleed Event in Previously Untreated Patients with Hemophilia B: A Post Hoc Analysis of the PUPs B-LONG Trial. Blood 2021, 138: 498. DOI: 10.1182/blood-2021-148765.
- Messenger H, He C, Recht M, Kulkarni R. A Cross-Sectional Study of the American Thrombosis and Hemostasis Network Dataset for Outcomes of Dental Extractions in People with Hemophilia. Blood 2021, 138: 346. DOI: 10.1182/blood-2021-148498.
- Malec L, Hirsh N, O'Neill C, Watson C, Recht M. ATHN Transcends: A Natural History Cohort Study of the Safety, Effectiveness and Practice of Treatment in People with Non-Neoplastic Hematologic Disorders. Blood 2021, 138: 4242. DOI: 10.1182/blood-2021-148209.
- Santaella M, Witkop M, Mills K, Recht M, DiMichele D, Valentino L. National Hemophilia Foundation Enlists Diverse Patient Voices to Inform a National Research Blueprint for Inherited Bleeding Disorders. Blood 2021, 138: 1904. DOI: 10.1182/blood-2021-147857.
- Young G, Pipe S, Hermans C, Carcao M, Castaman G, Davis J, Ducore J, Dunn A, Escobar M, Journeycake J, Khan O, Mahlangu J, Meeks S, Mitha I, Négrier C, Nowak-Göttl U, Recht M, Chrisentery-Singleton T, Stasyshyn O, Vilchevska K, Martinez L, Wang M, Windyga J, Alexander W, Al-Sabbagh A, Bonzo D, Macie C, Mitchell I, Wilkinson T, Shapiro A. Eptacog Beta Efficacy in Children and Adolescents with Hemophilia A or B and Inhibitors: Subset Analysis Suggests Improved Caregiver Capacity to Assess Bleeding Episode Resolution with Subject Age. Blood 2021, 138: 3195. DOI: 10.1182/blood-2021-147434.
- Buckner T, Carpenter S, Daoud N, Hirsh N, McLean T, O'Neill C, Raffini L, Zia A, Recht M. Hemophilia Natural History Study (ATHN 7): Safety of Current Therapies for People with Hemophilia A or B. Blood 2021, 138: 2105. DOI: 10.1182/blood-2021-146726.
- Chrisentery-Singleton T, Alexander W, Al-Sabbagh A, Bonzo D, Callaghan M, Escobar M, Giermasz A, Hirsh N, Journeycake J, Nasr S, Quon D, Recht M. Athn 16: Safety of Coagulation Factor VIIa (recombinant)-Jncw for the Treatment of Bleeding Events in Patients with Congenital Hemophilia a or B with Inhibitors with or without Prophylactic Treatment. Blood 2021, 138: 3201. DOI: 10.1182/blood-2021-146247.
- Journeycake J, Cheng D, Chrisentery-Singleton T, Desai V, von Drygalski A, Fedor C, Hirsh N, Patel B, Raffini L, Recht M, Sidinio R, Wang M, Zhang X, Neufeld E. Reduced Dosing Frequency Following a Switch to Rix-FP for the Treatment of Hemophilia B: Results from the Athn 2 Study. Blood 2021, 138: 1039. DOI: 10.1182/blood-2021-144617.
- Veeranki S, Pednekar P, Graf M, Tuly R, Recht M, Batt K. A Delphi Consensus Approach for Difficult-to-Treat Patients with Severe Hemophilia A without Inhibitors. Journal Of Blood Medicine 2021, 12: 913-928. PMID: 34707422, PMCID: PMC8544791, DOI: 10.2147/jbm.s334852.
- Valentino L, Baker J, Butler R, Escobar M, Frick N, Karp S, Koulianos K, Lattimore S, Nugent D, Pugliese J, Recht M, Reding M, Rice M, Thibodeaux C, Skinner M. Integrated Hemophilia Patient Care via a National Network of Care Centers in the United States: A Model for Rare Coagulation Disorders. Journal Of Blood Medicine 2021, 12: 897-911. PMID: 34707421, PMCID: PMC8544265, DOI: 10.2147/jbm.s325031.
- Konkle B, Quon D, Raffini L, Recht M, Radulescu V, Carpenter S, Dunn A, Lu M, Watt M. A Prospective Observational Study of Antihemophilic Factor (Recombinant) Prophylaxis Related to Physical Activity Levels in Patients with Hemophilia A in the United States (SPACE). Journal Of Blood Medicine 2021, 12: 883-896. PMID: 34703348, PMCID: PMC8523903, DOI: 10.2147/jbm.s327180.
- Escobar M, Castaman G, Boix S, Callaghan M, de Moerloose P, Ducore J, Hermans C, Journeycake J, Leissinger C, Luck J, Mahlangu J, Miesbach W, Mitha I, Négrier C, Quon D, Recht M, Schved J, Shapiro A, Sidonio R, Srivastava A, Stasyshyn O, Vilchevska K, Wang M, Young G, Alexander W, Al‐Sabbagh A, Bonzo D, Macie C, Wilkinson T, Kessler C. The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors. Haemophilia 2021, 27: 921-931. PMID: 34636112, PMCID: PMC9292935, DOI: 10.1111/hae.14419.
- Garrison L, Pezalla E, Towse A, Yang H, Faust E, Wu E, Li N, Sawyer E, Recht M. Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations. Value In Health 2021, 24: 1628-1633. PMID: 34711363, DOI: 10.1016/j.jval.2021.05.008.
- Witkop M, Morgan G, O'Hara J, Recht M, Buckner T, Nugent D, Curtis R, O'Mahony B, Skinner M, Mulhern B, Cawson M, Ali T, Sawyer E, Li N. Patient preferences and priorities for haemophilia gene therapy in the US: A discrete choice experiment. Haemophilia 2021, 27: 769-782. PMID: 34310811, PMCID: PMC9290457, DOI: 10.1111/hae.14383.
- Nolan B, Klukowska A, Shapiro A, Rauch A, Recht M, Ragni M, Curtin J, Gunawardena S, Mukhopadhyay S, Jayawardene D, Winding B, Fischer K, Liesner R. Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B. Blood Advances 2021, 5: 2732-2739. PMID: 34242387, PMCID: PMC8288672, DOI: 10.1182/bloodadvances.2020004085.
- Miesbach W, Giermasz A, Castaman G, Key N, Lattimore S, Leebeek F, von Drygalski A, Recht M, Gomez E, Gut R, Pipe S. Gene Transfer with Etranacogene dezaparvovec (AAV5-Padua hFIX variant) in Adults with Severe or Moderate-Severe Hemophilia B: Two Year Data from a Phase 2b Trial. Hämostaseologie 2021, 41: s6. DOI: 10.1055/s-0041-1728090.
- Sampson M, Cheng D, Recht M, Fargo J. The effect of age at diagnosis of type 1 von Willebrand disease on diagnostic laboratory values: A paediatric perspective. Haemophilia 2021, 27: e412-e414. PMID: 33533138, DOI: 10.1111/hae.14265.
- Li N, Sawyer E, Maruszczyk K, Guzauskas G, Slomka M, Burke T, Martin A, O’Hara J, Stevenson M, Recht M. Adult lifetime cost of hemophilia B management in the US: payer and societal perspectives from a decision analytic model. Journal Of Medical Economics 2021, 24: 363-372. PMID: 33591884, DOI: 10.1080/13696998.2021.1891088.
- Witkop M, Wang M, Hernandez G, Recht M, Baumann K, Cooper D. Impact of haemophilia on patients with mild‐to‐moderate disease: Results from the P‐FiQ and B‐HERO‐S studies. Haemophilia 2021, 27: 8-16. PMID: 33522654, DOI: 10.1111/hae.14251.
- Recht M. Safety first: Tracking adverse events associated with new therapies for people with hemophilia. Journal Of Thrombosis And Haemostasis 2021, 19: 3-5. PMID: 33331044, DOI: 10.1111/jth.15188.
- Reipert B, Gangadharan B, Hofbauer C, Berg V, Schweiger H, Bowen J, Blatny J, Fijnvandraat K, Mullins E, Klintman J, Male C, McGuinn C, Meeks S, Radulescu V, Ragni M, Recht M, Shapiro A, Staber J, Yaish H, Santagostino E, Brown D. The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development. Blood Advances 2020, 4: 5785-5796. PMID: 33232473, PMCID: PMC7686884, DOI: 10.1182/bloodadvances.2020002731.
- von Drygalski A, Giermasz A, Castaman G, Key N, Lattimore S, Leebeek F, Miesbach W, Recht M, Gomez E, Gut R, Pipe S. Etranacogene Dezaparvovec (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B: Two Year Data from a Phase 2b Trial. Blood 2020, 136: 13. DOI: 10.1182/blood-2020-139295.
- Buckner T, Carpenter S, Croteau S, Cuker A, Daoud N, Kempton C, Malec L, McLean T, Raffini L, Staber J, Wang M, Watson C, Zia A, Recht M. Hemophilia Natural History Study (ATHN 7): Baseline Characteristics, Adverse Events, and Self-Reported Health Status of Individuals with Hemophilia a and B. Blood 2020, 136: 2-3. DOI: 10.1182/blood-2020-137696.
- Johnsen J, Fletcher S, Dove A, McCracken H, Martin B, Kircher M, Josephson N, Shendure J, Ruuska S, Valentino L, Pierce G, Watson C, Cheng D, Recht M, Konkle B. Results of Genetic Analysis of 11,341 Participants Enrolled in the My Life, Our Future (MLOF) Hemophilia Genotyping Initiative. Blood 2020, 136: 19. DOI: 10.1182/blood-2020-140649.
- Journeycake J, Recht M, Guelcher C, Neufeld E, Ragni M, Sidonio R, Takemoto C, Tarantino M, Cheng D, Lattimore S, Caicedo J, Denne M. Dosing, Patient Satisfaction and Other Patient-Reported Outcomes after Switching to Rurioctocog Alfa Pegol in Athn 2: A Longitudinal, Observational Study of Previously Treated Hemophilia Patients Switching Coagulation Replacement Factor Products. Blood 2020, 136: 17-18. DOI: 10.1182/blood-2020-138898.
- Pipe S, Recht M, Callaghan M, Sidonio R, Grandoni J, Duretz V, Bonzo D, Plantier J, Evans S, Mitchell I, Hermans C. In Vitro Evaluation of Thrombin Generation of Eptacog Beta (Factor VIIa, Recombinant) and Emicizumab in Congenital Hemophilia Α Plasma with and without Inhibitors. Blood 2020, 136: 41-42. DOI: 10.1182/blood-2020-136430.
- Lim M, Cheng D, Recht M, Kempton C, Key N. Management of inhibitors in persons with non‐severe hemophilia A in the United States. American Journal Of Hematology 2020, 96: e9-e11. PMID: 32976635, DOI: 10.1002/ajh.26011.
- Lim M, Cheng D, Recht M, Kempton C, Key N. Inhibitors and mortality in persons with nonsevere hemophilia A in the United States. Blood Advances 2020, 4: 4739-4747. PMID: 33007074, PMCID: PMC7556148, DOI: 10.1182/bloodadvances.2020002626.
- Goldscheitter G, Recht M, Sochacki P, Manco‐Johnson M, Taylor J. Biomarkers of bone disease in persons with haemophilia. Haemophilia 2020, 27: 149-155. PMID: 32856388, DOI: 10.1111/hae.13986.
- Ahuja S, Recht M, Konkle B. Hemostatic Therapies for Heavy Menstrual Bleeding. 2020, 119-127. DOI: 10.1007/978-3-030-48446-0_11.
- Malec L, Cheng D, Witmer C, Jaffray J, Kouides P, Haley K, Sidonio R, Johnson K, Recht M, White G, Croteau S, Ragni M. The impact of extended half‐life factor concentrates on prophylaxis for severe hemophilia in the United States. American Journal Of Hematology 2020, 95: 960-965. PMID: 32356313, DOI: 10.1002/ajh.25844.
- Wang M, Recht M, Iyer N, Cooper D, Soucie J. Hemophilia without prophylaxis: Assessment of joint range of motion and factor activity. Research And Practice In Thrombosis And Haemostasis 2020, 4: e12347. PMID: 32864554, PMCID: PMC7443428, DOI: 10.1002/rth2.12347.
- Marshall A, Recht M, Sridharan M, Nichols W, Ashrani A, Fischer K, Miles M, Riedel A, Pruthi R. A study of dedicated haemophilia carrier clinics in the United States: Prevalence, services offered and barriers to development. Haemophilia 2020, 26: e253-e255. PMID: 32537802, DOI: 10.1111/hae.14071.
- Warren B, Thornhill D, Stein J, Fadell M, Ingram J, Funk S, Norton K, Lane H, Bennett C, Dunn A, Recht M, Shapiro A, Manco-Johnson M. Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study. Blood Advances 2020, 4: 2451-2459. PMID: 32492157, PMCID: PMC7284094, DOI: 10.1182/bloodadvances.2019001311.
- Konkle B, Recht M, Hilger A, Marks P. The critical need for postmarketing surveillance in gene therapy for haemophilia. Haemophilia 2020, 27: 126-131. PMID: 32495492, DOI: 10.1111/hae.13972.
- Buckner T, Watson C, Recht M. Emicizumab in Hemophilia A. New England Journal Of Medicine 2020, 382: 785-786. PMID: 32074441, DOI: 10.1056/nejmc1916299.
- Haley K, Sidonio R, Abraham S, Cheng D, Recht M, Kulkarni R. A Cross-Sectional Study of Women and Girls with Congenital Bleeding Disorders: The American Thrombosis and Hemostasis Network Cohort. Journal Of Women's Health 2020, 29: 670-676. PMID: 31905045, DOI: 10.1089/jwh.2019.7930.
- Pipe S, Giermasz A, Castaman G, Key N, Lattimore S, Leebeek F, Miesbach W, Recht M, Gomez E, Long A, Gut R, von Drygalski A. One Year Data from a Phase 2b Trial of AMT-061 (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B. Blood 2019, 134: 3348. DOI: 10.1182/blood-2019-128765.
- Von Drygalski A, Giermasz A, Castaman G, Key N, Lattimore S, Leebeek F, Miesbach W, Recht M, Long A, Gut R, Sawyer E, Pipe S. Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B. Blood Advances 2019, 3: 3241-3247. PMID: 31698454, PMCID: PMC6855101, DOI: 10.1182/bloodadvances.2019000811.
- Konkle B, Recht M, Group T. The national blueprint for 21st century data and specimen collection and observational cohort studies: NHLBI State of the Science Workshop on factor VIII inhibitors. Haemophilia 2019, 25: 590-594. PMID: 31329362, DOI: 10.1111/hae.13772.
- Warren B, Jacobson L, Kempton C, Buchanan G, Recht M, Brown D, Leissinger C, Shapiro A, Abshire T, Manco‐Johnson M, Investigators F. Factor VIII prophylaxis effects outweigh other hemostasis contributors in predicting severe haemophilia A joint outcomes. Haemophilia 2019, 25: 867-875. PMID: 31115111, PMCID: PMC7273872, DOI: 10.1111/hae.13778.
- Mahlangu J, Oldenburg J, Callaghan M, Shima M, Mancuso M, Trask P, Recht M, Garcia C, Yang R, Lehle M, Macharia H, Asikanius E, Levy G, Kruse‐Jarres R, von Mackensen S. Health‐related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non‐interventional study (NIS). Haemophilia 2019, 25: 382-391. PMID: 31016855, PMCID: PMC6850115, DOI: 10.1111/hae.13731.
- Aledort L, Carpenter S, Cuker A, Kulkarni R, Recht M, Young G, Leissinger C. Why plasma‐derived factor VIII? Haemophilia 2019, 25: e183-e185. PMID: 30866124, DOI: 10.1111/hae.13705.
- Samuelson Bannow B, Recht M, Négrier C, Hermans C, Berntorp E, Eichler H, Mancuso M, Klamroth R, O'Hara J, Santagostino E, Matsushita T, Kessler C. Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis. Blood Reviews 2019, 35: 43-50. PMID: 30922616, DOI: 10.1016/j.blre.2019.03.002.
- Miesbach W, Castaman G, Key N, Lattimore S, Leebeek F, Von Drygalski A, Zelenkofske S, Recht M, Pipe S. Phase 2b Trial of AMT-061 (AAV5-Padua hFIX): Translation into Humans of an Enhanced Gene Transfer Vector for Adults with Severe or Moderate-severe Hemophilia B. Hämostaseologie 2019, 39: s1-s92. DOI: 10.1055/s-0039-1680141.
- Miesbach W, Castaman G, Key N, Lattimore S, Leebeek F, Zelenkofske S, Recht M, Pipe S. HOPE-B: Study Design of a Phase III trial of an Investigational Gene Therapy AMT-061 in Subjects with Severe or Moderately Severe Hemophilia B. Hämostaseologie 2019, 39: s1-s92. DOI: 10.1055/s-0039-1680217.
- Winsnes K, Sochacki P, Eriksson C, Shereck E, Recht M, Johnson K, De Mola R, Stork L. Delirium in the pediatric hematology, oncology, and bone marrow transplant population. Pediatric Blood & Cancer 2019, 66: e27640. PMID: 30697919, DOI: 10.1002/pbc.27640.
- Warren B, Thornhill D, Stein J, Fadell M, Funk S, Lane H, Bennett C, Shapiro A, Recht M, Manco-Johnson M. Early Prophylaxis Provides Continued Joint Protection in Severe Hemophilia A: Results of the Joint Outcome Continuation Study. Blood 2018, 132: 382. DOI: 10.1182/blood-2018-99-117413.
- Nathwani A, Reiss U, Tuddenham E, Chowdary P, McIntosh J, Riddell A, Pie J, Mahlangu J, Recht M, Shen Y, Halka K, Meagher M, Nienhuis A, Davidoff A, Mangles S, Morton C, Junfang Z, Radulescu V. Adeno-Associated Mediated Gene Transfer for Hemophilia B:8 Year Follow up and Impact of Removing “Empty Viral Particles” on Safety and Efficacy of Gene Transfer. Blood 2018, 132: 491. DOI: 10.1182/blood-2018-99-118334.
- Gangadharan B, Reipert B, Berg V, Scheiflinger F, Blatny J, Fijnvandraat K, Gruppo R, Klintman J, Male C, McGuinn C, Meeks S, Radulescu V, Ragni M, Recht M, Santagostino E, Shapiro A, Staber J, Yaish H, Yee D, Brown D. Data Coming out of the Human Inhibitor PUP Study (HIPS) Reveal 4 Subgroups of Patients with Distinct Antibody Signatures. Blood 2018, 132: 3774. DOI: 10.1182/blood-2018-99-115979.
- Mahlangu J, Oldenburg J, Callaghan M, Shima M, Santagostino E, Moore M, Recht M, Garcia C, Yang R, Lehle M, Macharia H, Asikanius E, Levy G, Kruse‐Jarres R. Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multi‐centre, non‐interventional study. Haemophilia 2018, 24: 921-929. PMID: 30295389, DOI: 10.1111/hae.13612.
- Croteau S, Callaghan M, Davis J, Dunn A, Guerrera M, Khan O, Neufeld E, Raffini L, Recht M, Wang M, Iorio A. Focusing in on use of pharmacokinetic profiles in routine hemophilia care. Research And Practice In Thrombosis And Haemostasis 2018, 2: e12118. PMID: 30046766, PMCID: PMC6046597, DOI: 10.1002/rth2.12118.
- Manco‐Johnson M, Byams V, Recht M, Dudley B, Dupervil B, Aschman D, Oakley M, Kapica S, Voutsis M, Humes S, Kulkarni R, Grant A, Network. O. Community counts: Evolution of a national surveillance system for bleeding disorders. American Journal Of Hematology 2018, 93: e137-e140. PMID: 29473207, PMCID: PMC6145085, DOI: 10.1002/ajh.25076.
- Roberts J, Lattimore S, Recht M, Jackson S, Gue D, Squire S, Robinson K, Price V, Denne M, Richardson S, Rockwood K. Goal Attainment Scaling for haemophilia (GAS‐Hēm): testing the feasibility of a new patient‐centric outcome measure in people with haemophilia. Haemophilia 2018, 24: e199-e206. PMID: 29626387, DOI: 10.1111/hae.13454.
- Batt K, Boggio L, Neff A, Buckner T, Wang M, Quon D, Witkop M, Recht M, Kessler C, Iyer N, Cooper D. Patient‐reported outcomes and joint status across subgroups of US adults with hemophilia with varying characteristics: Results from the Pain, Functional Impairment, and Quality of Life (P‐FiQ) study. European Journal Of Haematology 2018, 100: 14-24. PMID: 29498783, DOI: 10.1111/ejh.13028.
- Buckner T, Batt K, Quon D, Witkop M, Recht M, Kessler C, Baumann K, Hernandez G, Wang M, Cooper D, Kempton C. Assessments of pain, functional impairment, anxiety, and depression in US adults with hemophilia across patient‐reported outcome instruments in the Pain, Functional Impairment, and Quality of Life (P‐FiQ) study. European Journal Of Haematology 2018, 100: 5-13. PMID: 29498784, DOI: 10.1111/ejh.13027.
- Rocheleau A, Khader A, Ngo A, Boehnlein C, McDavitt C, Lattimore S, Recht M, McCarty O, Haley K. Pilot study of novel lab methodology and testing of platelet function in adolescent women with heavy menstrual bleeding. Pediatric Research 2018, 83: 693-701. PMID: 29166373, PMCID: PMC5902421, DOI: 10.1038/pr.2017.298.
- Kempton C, Recht M, Neff A, Wang M, Buckner T, Soni A, Quon D, Witkop M, Boggio L, Gut R, Cooper D. Impact of pain and functional impairment in US adults with haemophilia: Patient‐reported outcomes and musculoskeletal evaluation in the pain, functional impairment and quality of life (P‐FiQ) study. Haemophilia 2017, 24: 261-270. PMID: 29218759, DOI: 10.1111/hae.13377.
- Kruse-Jarres R, Callaghan M, Croteau S, Jimenez-Yuste V, Khoo L, Liesner R, Matsushita T, Recht M, Young G, Chang T, Dhalluin C, Mu Y, Xu J, Devenport J, Ko R, Solari P, Oldenburg J. Surgical Experience in Two Multicenter, Open-Label Phase 3 Studies of Emicizumab in Persons with Hemophilia A with Inhibitors (HAVEN 1 and HAVEN 2). Blood 2017, 130: 89. DOI: 10.1182/blood.v130.suppl_1.89.89.
- Gangadharan B, Reipert B, Scheiflinger F, Bowen J, Donnachie E, van Draat K, Gruppo R, Klintman J, Male C, McGuinn C, Meeks S, Recht M, Ragni M, Yaish H, Shapiro A, Yee D, Radulescu V, Santagostino E, Brown D. Longitudinal Antibody Signatures Following FVIII Replacement Therapy in Previously Untreated Patients with Severe Hemophilia Α- New Insights from the Hemophilia Inhibitor PUP Study (HIPS). Blood 2017, 130: 88. DOI: 10.1182/blood.v130.suppl_1.88.88.
- Wang M, Recht M, Iyer N, Cooper D, Soucie J. The Relationship of Joint Range of Motion to Factor Activity in Patients with Hemophilia A and B without Prophylaxis: A Longitudinal Assessment of the CDC-UDC Hemophilia Dataset. Blood 2017, 130: 756. DOI: 10.1182/blood.v130.suppl_1.756.756.
- Kempton C, Wang M, Recht M, Neff A, Shapiro A, Soni A, Kulkarni R, Buckner T, Batt K, Iyer N, Cooper D. Reliability of patient-reported outcome instruments in US adults with hemophilia: the Pain, Functional Impairment and Quality of life (P-FiQ) study. Patient Preference And Adherence 2017, 11: 1603-1612. PMID: 29033549, PMCID: PMC5614789, DOI: 10.2147/ppa.s141389.
- Batt K, Recht M, Cooper D, Iyer N, Kempton C. Construct validity of patient-reported outcome instruments in US adults with hemophilia: results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study. Patient Preference And Adherence 2017, 11: 1369-1380. PMID: 28860720, PMCID: PMC5558590, DOI: 10.2147/ppa.s141390.
- Ullman M, Zhang Q, Grosse S, Recht M, Soucie J, Investigators T. Prophylaxis use among males with haemophilia B in the United States. Haemophilia 2017, 23: 910-917. PMID: 28780772, PMCID: PMC5724962, DOI: 10.1111/hae.13317.
- Shatzel J, Azar S, Scherber R, Gay N, Deloughery T, VanSandt A, Kruse‐Jarres R, Recht M, Taylor J. Unexpected pharmacokinetics of recombinant porcine factor VIII in a patient with acquired factor VIII deficiency and spontaneous epidural haematoma. Haemophilia 2017, 23: e453-e456. PMID: 28664642, DOI: 10.1111/hae.13247.
- Kahan S, Cuker A, Kushner R, Maahs J, Recht M, Wadden T, Willis T, Majumdar S, Ungar D, Cooper D. Prevalence and impact of obesity in people with haemophilia: Review of literature and expert discussion around implementing weight management guidelines. Haemophilia 2017, 23: 812-820. PMID: 28636076, DOI: 10.1111/hae.13291.
- Recht M, Rajpurkar M, Chitlur M, d'Oiron R, Zotz R, Di Minno G, Cooper D, Poon M. Independent adjudicator assessments of platelet refractoriness and rFVIIa efficacy in bleeding episodes and surgeries from the multinational Glanzmann's thrombasthenia registry. American Journal Of Hematology 2017, 92: 646-652. PMID: 28370369, DOI: 10.1002/ajh.24741.
- Witkop M, Neff A, Buckner T, Wang M, Batt K, Kessler C, Quon D, Boggio L, Recht M, Baumann K, Gut R, Cooper D, Kempton C. Self‐reported prevalence, description and management of pain in adults with haemophilia: methods, demographics and results from the Pain, Functional Impairment, and Quality of life (P‐FiQ) study. Haemophilia 2017, 23: 556-565. PMID: 28419637, DOI: 10.1111/hae.13214.
- Chitlur M, Rajpurkar M, Recht M, Tarantino M, Yee D, Cooper D, Gunawardena S. Recognition and management of platelet-refractory bleeding in patients with Glanzmann’s thrombasthenia and other severe platelet function disorders. International Journal Of General Medicine 2017, 10: 95-99. PMID: 28435309, PMCID: PMC5388206, DOI: 10.2147/ijgm.s128953.
- Buckner T, Witkop M, Guelcher C, Frey M, Hunter S, Peltier S, Recht M, Walsh C, Kessler C, Owens W, Clark D, Frick N, Rice M, Iyer N, Holot N, Cooper D, Sidonio R. Management of US men, women, and children with hemophilia and methods and demographics of the Bridging Hemophilia B Experiences, Results and Opportunities into Solutions (B‐HERO‐S) study. European Journal Of Haematology 2017, 98: 5-17. PMID: 28319338, DOI: 10.1111/ejh.12854.
- Oleson D, Fox L, Nguyen T, Sochacki P, McCarthy M, Adams E, Recht M. A comparison of two types of ankle supports in men with haemophilia and unilateral ankle pain from arthropathy. Haemophilia 2017, 23: 444-448. PMID: 28220573, DOI: 10.1111/hae.13184.
- Recht M, Chitlur M, Lam D, Sarnaik S, Rajpurkar M, Cooper D, Gunawardena S. Epistaxis as a Common Presenting Symptom of Glanzmann’s Thrombasthenia, a Rare Qualitative Platelet Disorder: Illustrative Case Examples. Case Reports In Emergency Medicine 2017, 2017: 8796425. PMID: 28299211, PMCID: PMC5337314, DOI: 10.1155/2017/8796425.
- Mahlangu J, Oldenburg J, Callaghan M, Shima M, Santagostino E, Lehle M, Uguen M, Hirst C, Moore M, Recht M, Garcia C, Yang R, Kruse-Jarres R. Bleeding Events and Safety Outcomes in Patients with Hemophilia a with Inhibitors: A Prospective, Multicenter, Non-Interventional Study. Blood 2016, 128: 3800. DOI: 10.1182/blood.v128.22.3800.3800.
- Batt K, Recht M, Wang M, Quon D, Boggio L, Kessler C, Buckner T, Neff A, Iyer N, Cooper D, Kempton C. Linear and Logistic Regression Models of Patient-Reported Outcomes and Patient Characteristics in US Adults with Hemophilia from the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study. Blood 2016, 128: 252. DOI: 10.1182/blood.v128.22.252.252.
- Haley K, Lattimore S, McDavitt C, Khader A, Boehnlein C, Baker-Groberg S, Ngo A, McCarty O, Recht M. Identification of Qualitative Platelet Disorders in Adolescent Women with Heavy Menstrual Bleeding. Blood 2016, 128: 4922. DOI: 10.1182/blood.v128.22.4922.4922.
- Janic D, Matytsina I, Misgav M, Oldenburg J, Ozelo M, Recht M, Korsholm L, Savic A, Santagostino E. Safety and Efficacy of Turoctocog Alfa in Prevention and on-Demand Treatment of Bleeding Episodes in Patients with Hemophilia A. Blood 2016, 128: 3790. DOI: 10.1182/blood.v128.22.3790.3790.
- Reipert B, Gangadharan B, Hofbauer C, Scheiflinger F, Bowen J, Donnachie E, Fijvandraat K, Gruppo R, Klintman J, Male C, McGuinn C, Meeks S, Recht M, Ragni M, Yaish H, Santagostino E, Brown D. Appearance of High-Affinity Antibodies Precedes Clinical Diagnosis of FVIII Inhibitors - Preliminary Analysis from the Hemophilia Inhibitor PUP Study (HIPS). Blood 2016, 128: 328. DOI: 10.1182/blood.v128.22.328.328.
- Aledort L, Recht M, Kulkarni R, Kobrinsky N. Adult, previously untreated patients remain a significant therapeutic challenge. Journal Of Thrombosis And Haemostasis 2016, 14: 2075-2076. PMID: 27496600, DOI: 10.1111/jth.13434.
- Recht M, Konkle B, Jackson S, Neufeld E, Rockwood K, Pipe S. Recognizing the need for personalization of haemophilia patient‐reported outcomes in the prophylaxis era. Haemophilia 2016, 22: 825-832. PMID: 27581872, DOI: 10.1111/hae.13066.
- Lentz S, Cerqueira M, Janic D, Kempton C, Matytsina I, Misgav M, Oldenburg J, Ozelo M, Recht M, Rosholm A, Savic A, Suzuki T, Tiede A, Santagostino E. Interim results from a large multinational extension trial (guardian™2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A. Haemophilia 2016, 22: e445-e449. PMID: 27291066, DOI: 10.1111/hae.12990.
- Batt K, Recht M, Cooper D, Iyer N, Kempton C. PRM123 CONSTRUCT VALIDITY OF PATIENT-REPORTED OUTCOME INSTRUMENTS IN US ADULT PEOPLE WITH HEMOPHILIA (PWH): RESULTS FROM THE PAIN, FUNCTIONAL IMPAIRMENT, AND QUALITY OF LIFE (P-FIQ) STUDY. Value In Health 2016, 19: a93. DOI: 10.1016/j.jval.2016.03.1737.
- Baker‐Groberg S, Lattimore S, Recht M, McCarty O, Haley K. Assessment of neonatal platelet adhesion, activation, and aggregation. Journal Of Thrombosis And Haemostasis 2016, 14: 815-827. PMID: 26806373, PMCID: PMC4828266, DOI: 10.1111/jth.13270.
- Despotovic J, Polfus L, Flanagan J, Bennett C, Lambert M, Neunert C, Kumar M, Klaassen R, Thornburg C, Jeng M, Recht M, Kirk S, Thompson A, Nugent D, Neufeld E, Bussel J, Boerwinkle E, Grace R. Genes Influencing the Development and Severity of Chronic ITP Identified through Whole Exome Sequencing. Blood 2015, 126: 73. DOI: 10.1182/blood.v126.23.73.73.
- Warren B, Jacobsen L, Villalobos-Menuey E, Abshire T, Shapiro A, Recht M, Brown D, Leissinger C, Kempton C, Lane H, Nugent D, Manco-Johnson M. Non-Factor VIII Coagulation Proteins Fail to Predict Joint Outcome in Severe Hemophilia a. Blood 2015, 126: 2289. DOI: 10.1182/blood.v126.23.2289.2289.
- Shatzel J, Azar S, Gay N, Luo J, Deloughery T, Recht M, Taylor J. The Clinical Associations and Outcomes of Patients Admitted with Acquired Hemophilia; A Review of the 2012 National Inpatient Sample. Blood 2015, 126: 1091. DOI: 10.1182/blood.v126.23.1091.1091.
- Kempton C, Recht M, Neff A, Wang M, Buckner T, Soni A, Quon D, Witkop M, Boggio L, Cooper D. Impact of Pain and Functional Impairment in US Adult People with Hemophilia (PWH): Patient-Reported Outcomes and Musculoskeletal Evaluation in the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study. Blood 2015, 126: 39. DOI: 10.1182/blood.v126.23.39.39.
- Mahlangu J, Weldingh K, Lentz S, Kaicker S, Karim F, Matsushita T, Recht M, Tomczak W, Windyga J, Ehrenforth S, Knobe K, Investigators F, Weltermann A, de Paula E, Cerqueira M, Zupancic‐Salek S, Katsarou O, Economou M, Nemes L, Boda Z, Santagostino E, Tagariello G, Hanabusa H, Fukutake K, Shima M, Serban M, Elezovic I, Savic A, Shen M, Chuansumrit A, Angchaisuksiri P, Kavakli K, Sasmaz I, Madan B, Giangrande P, Kempton C, Young G, Quon D, Ameri A, Kuriakose P, Obzut D, Wang M, Ortiz I. Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity. Journal Of Thrombosis And Haemostasis 2015, 13: 1989-1998. PMID: 26362483, DOI: 10.1111/jth.13141.
- Kempton C, Wang M, Recht M, Neff A, Shapiro A, Buckner T, Kulkarni R, Nugent D, Batt K, Wisniewski T, Cooper D. PSY58 Pain Functional Impairment and Quality of Life (P-FIQ): an assessment of reliability of five patient reported outcome (PRO) instruments in Adult People with Hemophilia (PWH). Value In Health 2015, 18: a301-a302. DOI: 10.1016/j.jval.2015.03.1756.
- Gay N, Lee S, Liel M, Sochacki P, Recht M, Taylor J. Increased fracture rates in people with haemophilia: a 10‐year single institution retrospective analysis. British Journal Of Haematology 2015, 170: 584-586. PMID: 25659575, DOI: 10.1111/bjh.13312.
- Haley K, Friedman K, Recht M. A Retrospective Analysis of Bleeding Phenotype and Von Willebrand Factor Exon 28 Polymorphism D1472H at a Single Institution. Blood 2014, 124: 2849. DOI: 10.1182/blood.v124.21.2849.2849.
- Larson E, Iwaniec U, Holmgren S, Turner R, Recht M, Taylor J. Age-Associated Bone Disease in Factor VIII-Deficient Mice. Blood 2014, 124: 2798. DOI: 10.1182/blood.v124.21.2798.2798.
- Recht M, Rajpurkar M, Chitlur M, Reding M, Frey M, Peltier S, Guelcher C, Stephens D, Cooper D. Impact of Glanzmann’s Thrombasthenia (GT): Perceptions from US Patients and Parents. Blood 2014, 124: 4853. DOI: 10.1182/blood.v124.21.4853.4853.
- Chitlur M, Recht M, Rajpurkar M, Neufeld E, Kessler C, Reding M, Tarantino M, Cooper D. Unmet Needs in Diagnosis and Treatment of Glanzmann’s Thrombasthenia (GT): Perceptions of US Hematologists and Nurses. Blood 2014, 124: 2179. DOI: 10.1182/blood.v124.21.2179.2179.
- Recht M, Lentz S, Zupancic-Šalek S, Matytsina I, Landorph A, Saugstrup T. Factor VIII Dosing and Preventive Efficacy in Obese Patients with Hemophilia (BMI ≥30 kg/m2) – a Post-Hoc Sub-Analysis of the guardian™ Trials. Blood 2014, 124: 1503. DOI: 10.1182/blood.v124.21.1503.1503.
- Maahs J, Donkin J, Recht M, Cooper D. Mixing and administration times of bypassing agents: observations from the Dosing Observational Study in Hemophilia (DOSE). Journal Of Blood Medicine 2014, 5: 153-156. PMID: 25187744, PMCID: PMC4149444, DOI: 10.2147/jbm.s61859.
- Recht M, Neufeld E, Sharma V, Solem C, Pickard A, Gut R, Cooper D. Impact of Acute Bleeding on Daily Activities of Patients with Congenital Hemophilia with Inhibitors and Their Caregivers and Families: Observations from the Dosing Observational Study in Hemophilia (DOSE). Value In Health 2014, 17: 744-748. PMID: 25236999, DOI: 10.1016/j.jval.2014.07.003.
- Rajpurkar M, Chitlur M, Recht M, Cooper D. Use of recombinant activated factor VII in patients with Glanzmann's thrombasthenia: a review of the literature. Haemophilia 2014, 20: 464-471. PMID: 24948404, DOI: 10.1111/hae.12473.
- Haley K, Recht M, McCarty O. Neonatal platelets: mediators of primary hemostasis in the developing hemostatic system. Pediatric Research 2014, 76: 230-237. PMID: 24941213, PMCID: PMC4348010, DOI: 10.1038/pr.2014.87.
- Haley K, Russell T, Boshkov L, Leger R, Garratty G, Recht M, Nazemi K. Fatal carboplatin-induced immune hemolytic anemia in a child with a brain tumor. Journal Of Blood Medicine 2014, 5: 55-58. PMID: 24868179, PMCID: PMC4031206, DOI: 10.2147/jbm.s59192.
- Adams E, Gloeckner S, Stadler D, Black A, Helm J, Recht M. Food insecurity is associated with household insurance status and number of affected children among families of children with hemophilia (805.14). The FASEB Journal 2014, 28 DOI: 10.1096/fasebj.28.1_supplement.805.14.
- Adams E, Deutsche J, Okoroh E, Owens‐McAlister S, Majumdar S, Ullman M, Damiano M, Recht M, Group T. An inventory of healthy weight practices in federally funded haemophilia treatment centres in the United States. Haemophilia 2014, 20: 639-643. PMID: 24629074, PMCID: PMC4484574, DOI: 10.1111/hae.12385.
- Haley K, Recht M, McCarty O. Development Of a Novel Method To Assess Neonatal Platelet Function. Blood 2013, 122: 4740. DOI: 10.1182/blood.v122.21.4740.4740.
- Manco-Johnson M, Manco-Johnson M, Blades T, Funk S, Lane H, McRedmond K, Dunn A, Recht M, Shapiro A, Valentino L, Brown D. Long-Term Orthopedic Effects Of Delaying Prophylaxis In Severe Hemophilia A Until Age 6 Years: Results Of The Joint Outcome Study Continuation (JOSc). Blood 2013, 122: 210. DOI: 10.1182/blood.v122.21.210.210.
- Recht M, Carly P, Larson E, Manco-Johnson M, Taylor J. Biomarkers Of Bone Disease In Subjects With Hemophilia. Blood 2013, 122: 1113. DOI: 10.1182/blood.v122.21.1113.1113.
- Recht M, Liel M, Turner R, Klein R, Taylor J. The bone disease associated with factor VIII deficiency in mice is secondary to increased bone resorption. Haemophilia 2013, 19: 908-912. PMID: 23731369, DOI: 10.1111/hae.12195.
- Soucie J, Monahan P, Kulkarni R, De Staercke C, Recht M, Chitlur M, Gruppo R, Hooper W, Kessler C, Manco‐Johnson M, Powell J, Pyle M, Riske B, Sabio H, Trimble S. Evidence for the continued transmission of parvovirus B19 in patients with bleeding disorders treated with plasma‐derived factor concentrates. Transfusion 2013, 53: 1143-1144. PMID: 23659532, DOI: 10.1111/trf.12153.
- Lentz S, Misgav M, Ozelo M, Šalek S, Veljkovic D, Recht M, Cerqueira M, Tiede A, Brand B, Mancuso M, Seremetis S, Lindblom A, Martinowitz U. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy. Haemophilia 2013, 19: 691-697. PMID: 23647704, DOI: 10.1111/hae.12159.
- Lane J, McLaren P, Dorrell L, Shianna K, Stemke A, Pelak K, Moore S, Oldenburg J, Alvarez-Roman M, Angelillo-Scherrer A, Boehlen F, Bolton-Maggs P, Brand B, Brown D, Chiang E, Cid-Haro A, Clotet B, Collins P, Colombo S, Dalmau J, Fogarty P, Giangrande P, Gringeri A, Iyer R, Katsarou O, Kempton C, Kuriakose P, Lin J, Makris M, Manco-Johnson M, Tsakiris D, Martinez-Picado J, Mauser-Bunschoten E, Neff A, Oka S, Oyesiku L, Parra R, Peter-Salonen K, Powell J, Recht M, Shapiro A, Stine K, Talks K, Telenti A, Wilde J, Yee T, Wolinsky S, Martinson J, Hussain S, Bream J, Jacobson L, Carrington M, Goedert J, Haynes B, McMichael A, Goldstein D, Fellay J, Immunology F. A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A. Human Molecular Genetics 2013, 22: 1903-1910. PMID: 23372042, PMCID: PMC3613165, DOI: 10.1093/hmg/ddt033.
- Soucie J, De Staercke C, Monahan P, Recht M, Chitlur M, Gruppo R, Hooper W, Kessler C, Kulkarni R, Manco‐Johnson M, Powell J, Pyle M, Riske B, Sabio H, Trimble S, Network H. Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma‐derived factor concentrates in the era of nucleic acid test screening. Transfusion 2012, 53: 1217-1225. PMID: 22998193, PMCID: PMC4519820, DOI: 10.1111/j.1537-2995.2012.03907.x.
- Neufeld E, Recht M, Sabio H, Saxena K, Solem C, Pickard A, Gut R, Cooper D. Effect of Acute Bleeding on Daily Quality of Life Assessments in Patients with Congenital Hemophilia with Inhibitors and Their Families: Observations from the Dosing Observational Study in Hemophilia. Value In Health 2012, 15: 916-925. PMID: 22999142, DOI: 10.1016/j.jval.2012.05.005.
- Auerswald G, Thompson A, Recht M, Brown D, Liesner R, Guzmán-Becerra N, Dyck-Jones J, Ewenstein B, Abbuehl B. Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A. Thrombosis And Haemostasis 2012, 107: 1072-1082. PMID: 22476554, PMCID: PMC6292131, DOI: 10.1160/th11-09-0642.
- Liel M, Greenberg D, Recht M, Vanek C, Klein R, Taylor J. Decreased bone density and bone strength in a mouse model of severe factor VIII deficiency. British Journal Of Haematology 2012, 158: 140-143. PMID: 22469061, DOI: 10.1111/j.1365-2141.2012.09101.x.
- Chiu Y, Drolet B, Blei F, Carcao M, Fangusaro J, Kelly M, Krol A, Lofgren S, Mancini A, Metry D, Recht M, Silverman R, Tom W, Pope E. Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach–Merritt phenomenon. Pediatric Blood & Cancer 2012, 59: 934-938. PMID: 22648868, PMCID: PMC3528889, DOI: 10.1002/pbc.24103.
- Richard N, Haley K, Recht M. Thalassemia. 2012, 3029-3036. DOI: 10.1007/978-3-642-02202-9_326.
- Flood V, Recht M. Autoimmune Hemolytic Anemia. 2012, 2969-2974. DOI: 10.1007/978-3-642-02202-9_319.
- Bradeen H, Shehab S, Recht M. Iron Metabolism and Iron Deficiency Anemia. 2012, 2963-2968. DOI: 10.1007/978-3-642-02202-9_318.
- Wong T, Majumdar S, Adams E, Bergman S, Damiano M, Deutsche J, Recht M, Group H. Overweight and Obesity in Hemophilia A Systematic Review of the Literature. American Journal Of Preventive Medicine 2011, 41: s369-s375. PMID: 22099360, DOI: 10.1016/j.amepre.2011.09.008.
- Soucie J, De Staercke C, Chitlur M, Gruppo R, Hooper W, Kessler C, Kulkarni R, Manco-Johnson M, Monahan P, Oakley M, Powell J, Pyle M, Recht M, Riske B, Sabio H, Trimble S. Continued Transmission of Parvovirus B19 in Plasma-Derived Factor Concentrates After the Implementation of B19 Nucleic Acid Plasma Minipool Screening,. Blood 2011, 118: 3378. DOI: 10.1182/blood.v118.21.3378.3378.
- Chang L, Price S, Perkins K, Davis J, Aldridge P, Recht M, Kelleher J, Rao V. Mycophenolate Mofetil and Thrombopoietin Receptor Agonists in the Treatment of Refractory Thrombocytopenia in Patients with Autoimmune Lymphoproliferative Syndrome. Blood 2011, 118: 2218. DOI: 10.1182/blood.v118.21.2218.2218.
- Liel M, Klein R, Recht M, Greenberg D, Taylor J. Reduced Bone Mineral Density in Factor VIII Deficient Mice and the Role of Inflammatory Cytokines. Blood 2011, 118: 21. DOI: 10.1182/blood.v118.21.21.21.
- Grace R, Bennett C, Ritchey A, Jeng M, Thornburg C, Lambert M, Neier M, Recht M, Kumar M, Blanchette V, Klaassen R, Buchanan G, Kurth M, Nugent D, Thompson A, Stine K, Kalish L, Neufeld E. Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia. Pediatric Blood & Cancer 2011, 58: 221-225. PMID: 21674758, PMCID: PMC3863944, DOI: 10.1002/pbc.23130.
- RECHT M, POLLMANN H, TAGLIAFERRI A, MUSSO R, JANCO R, NEUMAN W. A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B. Haemophilia 2011, 17: 494-499. PMID: 21518148, DOI: 10.1111/j.1365-2516.2011.02436.x.
- SOUCIE J, WANG C, SIDDIQI A, KULKARNI R, RECHT M, KONKLE B, NETWORK T. The longitudinal effect of body adiposity on joint mobility in young males with Haemophilia A. Haemophilia 2011, 17: 196-203. PMID: 21332880, DOI: 10.1111/j.1365-2516.2010.02400.x.
- Wong T, Recht M. Current Options and New Developments in the Treatment of Haemophilia. Drugs 2011, 71: 305-320. PMID: 21319868, DOI: 10.2165/11585340-000000000-00000.
- Grace R, Bennett C, Ritchey A, Jeng M, Thornburg C, Lambert M, Neier M, Recht M, Kumar M, Blanchette V, Klaassen R, Buchanan G, Kurth M, Nugent D, Thompson A, Stine K, Kalish L, Neufeld E. Response to Steroids Predicts Response to Rituximab In Pediatric Chronic Immune Thrombocytopenia. Blood 2010, 116: 3681. DOI: 10.1182/blood.v116.21.3681.3681.
- Grace R, Neufeld E, Ritchey A, Kumar M, Jeng M, Blanchette V, Klaassen R, Buchanan G, Kurth M, Nugent D, Thompson A, Thornburg C, Lambert M, Neier M, Recht M, Stine K, Kalish L, Bennett C. The North American Chronic Immune Thrombocytopenia Registry (NACIR): Demographics and Treatment Responses. Blood 2010, 116: 2509. DOI: 10.1182/blood.v116.21.2509.2509.
- Neufeld E, Recht M, Sabio H, Cooper D, Wilke C, Pickard A, Gut R. PSY46 EFFECT OF ACUTE BLEEDING EPISODES ON QUALITY OF LIFE (QOL) IN PATIENTS WITH CONGENITAL HEMOPHILIA WITH INHIBITORS (CHWI) AND THEIR FAMILIES: OBSERVATIONS OF BLEED VS. NON-BLEED DAY QOL FROM THE DOSING OBSERVATIONAL STUDY IN HEMOPHILIA (DOSE) AND IMPLICATIONS FOR ASSESSMENT AND PREDICTION. Value In Health 2010, 13: a214. DOI: 10.1016/s1098-3015(10)73048-5.
- Recht M, Neufeld E, Sharma V, Cooper P, Wilke C, Pickard A, Gut R. PSY45 IMPACT OF ACUTE BLEEDING AND ADMINISTRATION OF BYPASSING AGENTS (BPA) ON DAILY ACTIVITIES OF PATIENTS WITH CONGENITAL HEMOPHILIA WITH INHIBITORS (CHWI) AND THEIR CAREGIVERS AND FAMILIES: OBSERVATIONS FROM THE DOSING OBSERVATIONAL STUDY IN HEMOPHILIA (DOSE). Value In Health 2010, 13: a214. DOI: 10.1016/s1098-3015(10)73047-3.
- Recht M. Thrombocytopenia and Anemia in Infants and Children. Emergency Medicine Clinics Of North America 2009, 27: 505-523. PMID: 19646651, DOI: 10.1016/j.emc.2009.04.009.
- RECHT M, NEMES L, MATYSIAK M, MANCO‐JOHNSON M, LUSHER J, SMITH M, MANNUCCI P, HAY C, ABSHIRE T, O’BRIEN A, HAYWARD B, UDATA C, ROTH D, ARKIN S. Clinical evaluation of moroctocog alfa (AF‐CC), a new generation of B‐domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full‐length recombinant factor VIII. Haemophilia 2009, 15: 869-880. PMID: 19473411, DOI: 10.1111/j.1365-2516.2009.02027.x.
- VALENTINO L, RECHT M, DIPAOLA J, SHAPIRO A, PIPE S, EWING N, URGO J, BULLOCK T, SIMMONS M, DEGUZMAN C. Experience with a third generation recombinant factor VIII concentrate (Advate®) for immune tolerance induction in patients with haemophilia A. Haemophilia 2009, 15: 718-726. PMID: 19298383, DOI: 10.1111/j.1365-2516.2008.01960.x.
- SPENCER M, WODRICH D, SCHULTZ W, WAGNER L, RECHT M. Inattention, hyperactivity‐impulsivity, academic skills and psychopathology in boys with and without haemophilia. Haemophilia 2009, 15: 701-706. PMID: 19298375, DOI: 10.1111/j.1365-2516.2009.01993.x.
- GERSTNER G, DAMIANO M, TOM A, WORMAN C, SCHULTZ W, RECHT M, STOPECK A. Prevalence and risk factors associated with decreased bone mineral density in patients with haemophilia. Haemophilia 2009, 15: 559-565. PMID: 19187193, DOI: 10.1111/j.1365-2516.2008.01963.x.
- Manco-Johnson M, Wagner L, Recht M, Knoll C, Geraghty S, Pounder E, Goldenberg N. Successful Control of Refractory Inhibitors in Children with Hemophilia a Using Multiple Agent Immune Modulation. Blood 2008, 112: 2283. DOI: 10.1182/blood.v112.11.2283.2283.
- Gerstner G, Damiano M, Tom A, Worman C, Schultz W, Recht M, Stopeck A. Decreased Bone Mineral Density among Patients with Hemophilia. Blood 2007, 110: 1153. DOI: 10.1182/blood.v110.11.1153.1153.
- Recht M, Nemes L, O'Brien A, Udata C, Roth D, Arkin S. ReFacto AF Is Effective and Safe in Previously Treated Patients with Severe Hemophilia A: Final Results of a Pivotal Phase III Study. Blood 2007, 110: 1151. DOI: 10.1182/blood.v110.11.1151.1151.
- LAMBERT T, RECHT M, VALENTINO L, POWELL J, UDATA C, SULLIVAN S, ROTH D. Reformulated BeneFix®: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B. Haemophilia 2007, 13: 233-243. PMID: 17498071, DOI: 10.1111/j.1365-2516.2007.01458.x.
- Hay C, Recht M, Carcao M, Reipert B. Current and Future Approaches to Inhibitor Management and Aversion. Seminars In Thrombosis And Hemostasis 2006, 32: 015-021. PMID: 16804831, DOI: 10.1055/s-2006-946910.
- Powell J, Lambert T, Navarro F, Recht M, Sullivan S, Udata C, Lilly L, Roth D. A New Formulation of Recombinant Human Factor IX Is Bioequivalent to BeneFIX: A Double-Blind, Randomized, Crossover Pharmacokinetic and Open-Label Safety and Efficacy Study. Blood 2005, 106: 4076. DOI: 10.1182/blood.v106.11.4076.4076.
- Wodrich D, Recht M, Gradowski M, Wagner L. Is attention deficit hyperactivity disorder over‐represented among HIV‐seronegative boys with haemophilia? Preliminary results from our centre. Haemophilia 2003, 9: 593-597. PMID: 14511300, DOI: 10.1046/j.1365-2516.2003.00790.x.
- Rincón M, Enslen H, Raingeaud J, Recht M, Zapton T, Su M, Penix L, Davis R, Flavell R. Interferon‐γ expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway. The EMBO Journal 1998, 17: 2817-2829. PMID: 9582275, PMCID: PMC1170622, DOI: 10.1093/emboj/17.10.2817.
- Recht M, Xu S, Penix L. p38 MAP kinase is critical for the transcriptional regulation of the human interferon-γ gene. ♦ 58. Pediatric Research 1997, 41: 12-12. DOI: 10.1203/00006450-199704001-00079.
Departments and Programs
Locations
1
YNHCH Pediatric Specialty Center at Trumbull
Trumbull Pediatric Specialty Center
5520 Park Avenue, Ste 600
Trumbull, CT 06611
1 of 3
- YNHCH Pediatric Specialty Center at TrumbullTrumbull Pediatric Specialty Center5520 Park Avenue, Ste 600Trumbull, CT 06611
- Smilow Cancer HospitalSmilow Cancer Hospital at Yale New Haven35 Park Street, Wing North Pavilion Fl 7New Haven, CT 06511
- YNHCH Pediatric Specialty Center at Old SaybrookOld Saybrook Medical Center633 Middlesex Turnpike, Ste 110Old Saybrook, CT 06475
1
YNHCH Pediatric Specialty Center at Trumbull
Trumbull Pediatric Specialty Center
5520 Park Avenue, Ste 600
Trumbull, CT 06611
1 of 3
- YNHCH Pediatric Specialty Center at TrumbullTrumbull Pediatric Specialty Center5520 Park Avenue, Ste 600Trumbull, CT 06611
- Smilow Cancer HospitalSmilow Cancer Hospital at Yale New Haven35 Park Street, Wing North Pavilion Fl 7New Haven, CT 06511
- YNHCH Pediatric Specialty Center at Old SaybrookOld Saybrook Medical Center633 Middlesex Turnpike, Ste 110Old Saybrook, CT 06475